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TIIVISTELMÄ
Tämä tutkimus on osa Kansanterveyslaitoksen Mielenterveyden ja alkoholitutkimuksen 
osaston ja Helsingin ja Uudenmaan sairaanhoitopiirin Peijaksen sairaalan Psykiatrian 
tulosyksikön vakavan masennustilan tutkimusta. Tutkimus (Vantaa Depression Study, 
VDS) koostuu kahdesta osatutkimuksesta, 803 potilaan sairauskertomuksiin perus-
tuvasta osasta ja 269 potilaan seurantatutkimuksesta. Molemmissa tutkimusosioissa 
potilaat ovat erikoissairaanhoidon avohoito- ja sairaalapotilaita, joilla on todettu sairas-
tuminen uuteen masennusjaksoon. 
Tiedot sairauskertomuksiin perustuvaan tutkimukseen on kerätty potilaiden käynti- ja 
sairaalahoitotiedot sisältävistä tietokannoista. Tutkimukseen valikoitiin kaikki 20-59-
vuotiaat depressiopotilaat, joiden diagnoosi oli määritelty tautiluokituksen (ICD-10) 
mukaan masennustilaksi tai toistuvaksi masennukseksi ja joilla oli vähintään yksi 
avohoitokäynti tai sairaalahoitopäivä 1.1.1996-31.12.1996 välisenä aikana. Pois-
sulkukriteereinä olivat aiempi skitsofreniadiagnoosi, muu psykoosi tai kaksisuuntainen 
mielialahäiriö. Myös sellaiset potilaat suljettiin pois, joita oli hoidettu somaattisilla 
sairaalaosastoilla ja joiden hoidon suhteen oli pyydetty vain psykiatrin konsultaatiota. 
Tutkimukseen valittiin 290 mies- ja 513 naispotilasta. Näiden kaikkien sairaus-
kertomukset käytiin läpi ja niiden pohjalta täytettiin 57-kohtainen lomake. Potilaiden 
hoitoa seurattiin hoitojakson loppuun tai enintään vuoden 1997 loppuun. 
Useimmat (84%) saivat masennuslääkitystä, joskin pieni osa (11%) selvästi lääkkeen 
hoitotasoa alemmilla annoksilla. Hoitojakson aikana potilaat pääsivät psykiatrin 
vastaanotolle harvoin (mediaani kaksi käyntiä), mutta muille työntekijöille selvästi 
useammin (mediaani seitsemän käyntiä). Kummastakin sukupuolesta viidesosalla oli 
vähintään yksi sairaalahoitojakso (keskimäärin lähes kaksi) koko seuranta-aikana. 
Sairaalahoidon keskimääräinen kesto oli kaksi viikkoa. 
Masennuslääkkeiden käyttö oli varsin konservatiivista. Ensiksi aloitettu lääke 
vaihdettiin toiseen vain noin joka viidennellä (22%) ja vain kaksi potilasta sai yhteensä 
viittä eri masennuslääkettä. Vain 7% masennuslääkettä saaneista sai kahta lääkettä 
samanaikaisesti. Kukaan ei saanut muuta masennuslääkkeen tehoa parantavaa lää-
kitystä. Lääkityksestä kieltäytyminen oli tavallisin syy masennuslääkehoidon puut-
tumiseen. 
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Hoitojakson aikana 19%:lle niistä, jotka eivät hoidon alussa olleet eläkkeellä, myön-
nettiin työkyvyttömyyseläke psykiatrisen sairauden perusteella. Nämä potilaat olivat 
lähes yhdeksän vuotta vanhempia kuin ne, jotka eivät jääneet eläkkeelle. He olivat 
myös vakavammin sairaita, kävivät selvästi useammin hoitavan henkilön vastaanotolla 
ja käyttivät merkittävästi enemmän rinnakkaista lääkitystä (unilääkkeitä, rauhoittavia 
lääkkeitä ja psykoosilääkkeitä) kuin ne, jotka eivät jääneet eläkkeelle. 
Seurantatutkimuksessa seulottiin aluksi 806 aikuispotilasta iältään 20 - 59 vuotta 
mahdollisen uuden masennusjakson varalta. Näistä 542 potilasta haastateltiin kasvo-
tusten puolistrukturoidulla haastattelumenetelmällä (WHO Schedule for Clinical As-
sessment in Neuropsychiatry [SCAN], Version 2.0). Tutkimuksen poissulkukriteerit 
olivat vastaavat kuin sairauskertomuspohjaisessa tutkimuksessakin. Näistä 542 potilaas-
ta 269 täytti vakavan masennuksen kriteerit. Tässä tutkimuksessa kiinnitettiin erityisesti 
huomiota potilaiden huonoon toimintakykyyn, sosiaaliseen sopeutumiseen ja työkyvyt-
tömyyteen (sairauslomalla oloon tai eläköitymiseen) vaikuttaviin tekijöihin. 
Hoidon alussa tärkein yksittäinen sosiaaliseen ja toiminnalliseen kyvyttömyyteen 
vaikuttanut tekijä oli masennuksen vaikeusaste. Muita korkeammalla iällä ja per-
soonallisuushäiriöillä oli myös merkitystä. Koko masennusjakson kesto ja vaikeusaste, 
pelko-oireiset ahdistuneisuushäiriöt, alkoholismi ja persoonallisuushäiriöt vaikeuttivat 
sosiaalista sopeutumista. Työssä olevista lähes puolet (43%) oli sairauslomalla. Sai-
rauslomalla olon riskitekijöinä olivat masennuksen vaikeusaste, aiempien masen-
nusjaksojen määrä, naissukupuoli ja yli 50 vuoden ikä. 
Sosiaaliseen ja ammatilliseen toimintakyvyttömyyteen ja sosiaaliseen sopeutumiseen 
vaikuttavia tekijöitä tutkittiin 18 kuukauden seuranta-aikana. Potilaiden toimin-
takyvyttömyys ja sosiaalinen sopeutuminen paranivat samanaikaisesti depressiosta 
toipumisen myötä. Masennuksen vaikeusaste, aiemmat ja hoidon aikaiset uudet ma-
sennusjaksot, täyden toipumisen saavuttamattomuus ja masentuneena vietetty aika 
ennustivat kulloistakin toimintakyvyn ja sosiaalisen sopeutumisen astetta. Saman-
aikaisilla psyykkisillä häiriöillä, persoonallisuuden piirteillä (neurotisismi) ja koetulla 
sosiaalisella tuella oli myös vaikutuksensa. 
Seuranta-aikana (18 kuukautta) 269 potilaasta 13:lla (5%) potilaalla havaittiin ma-
sennuksen muuttuneen kaksisuuntaiseksi mielialahäiriöksi ja 58 (20%) jäi pois 
tutkimuksesta. Näistä 198:sta 186 ei ollut tutkimuksen alussa eläkkeellä. Heistä 21 jäi 
seuranta-aikana työkyvyttömyyseläkkeelle. Eläköityneet olivat muita selvästi vanhem-
pia, heillä oli muita harvemmin ammattikoulutus, ja he olivat selvästi useammin 
sairauslomalla kuin muut. Ryhmät eivät eronneet minkään muiden muuttujien suhteen. 
Masennuspotilaat saavat enimmäkseen riittävää masennuslääkitystä, mutta hoidon 
intensiteetissä ja seurannassa oli ongelmia. On haasteellista löytää suurimmassa toi-
mintakykynsä menettämisvaarassa olevat ja tarjota heille riittävää ja vaikuttavaa hoitoa. 
Koko yhteiskunta on haasteellisen tehtävän edessä voidakseen tarjota tarvittavat voima-
varat riittävän ja vaikuttavan hoidon toteuttamiseen. 
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1. ABSTRACT 
This study is one part of a collaborative depression research project, the Vantaa Depression 
Study (VDS), involving the Department of Mental and Alcohol Research of the National 
Public Health Institute, Helsinki, and the Department of Psychiatry of the Peijas Medical 
Care District (PMCD), Vantaa, Finland. The VDS includes two parts, a record-based study 
consisting of 803 patients, and a prospective, naturalistic cohort study of 269 patients. Both 
studies include secondary-level care psychiatric out- and inpatients with a new episode of 
major depressive disorder (MDD). 
Data for the record-based part of the study came from a computerised patient database 
incorporating all outpatient visits as well as treatment periods at the inpatient unit. We 
included all patients aged 20 to 59 years old who had been assigned a clinical diagnosis of 
depressive episode or recurrent depressive disorder according to the International 
Classification of Diseases, 10th edition (ICD-10) criteria and who had at least one outpatient 
visit or day as an inpatient in the PMCD during the study period January 1, 1996, to 
December 31, 1996. All those with an earlier diagnosis of schizophrenia, other non-affective 
psychosis, or bipolar disorder were excluded. Patients treated in the somatic departments of 
Peijas Hospital and those who had consulted but not received treatment from the psychiatric 
consultation services were excluded. The study sample comprised 290 male and 513 female 
patients. All their psychiatric records were reviewed and each patient completed a structured 
form with 57 items. The treatment provided was reviewed up to the end of the depression 
episode or to the end of 1997. 
Most (84%) of the patients received antidepressants, including a minority (11%) on 
treatment with clearly subtherapeutic low doses. During the treatment period the depressed 
patients investigated averaged only a few visits to psychiatrists (median two visits), but 
more to other health professionals (median seven). One-fifth of both genders were 
inpatients, with a mean of nearly two inpatient treatment periods during the overall 
treatment period investigated. The median length of a hospital stay was 2 weeks. 
Use of antidepressants was quite conservative: The first antidepressant had been switched to 
another compound in only about one-fifth (22%) of patients, and only two patients had 
received up to five antidepressant trials. Only 7% of those prescribed any antidepressant 
received two antidepressants simultaneously. None of the patients was prescribed any other 
Lopullinen.pdf   16 14.9.2006   10:36:25
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augmentation medication. Refusing antidepressant treatment was the most common 
explanation for receiving no antidepressants. 
During the treatment period, 19% of those not already receiving a disability pension were 
granted one due to psychiatric illness. These patients were nearly nine years older than those 
not pensioned. They were also more severely ill, made significantly more visits to 
professionals and received significantly more concomitant medications (hypnotics, 
anxiolytics, and neuroleptics) than did those receiving no pension. 
In the prospective part of the VDS, 806 adult patients were screened (aged 20-59 years) in 
the PMCD for a possible new episode of DSM-IV MDD. Of these, 542 patients were 
interviewed face-to-face with the WHO Schedules for Clinical Assessment in Neuro-
psychiatry (SCAN), Version 2.0. Exclusion criteria were the same as in the record-based 
part of the VDS. Of these, 542 269 patients fulfiled the criteria of DSM-IV MDE. This 
study investigated factors associated with patients’ functional disability, social adjustment, 
and work disability (being on sick-leave or being granted a disability pension). 
In the beginning of the treatment the most important single factor associated with overall 
social and functional disability was found to be severity of depression, but older age and 
personality disorders also significantly contributed. Total duration and severity of 
depression, phobic disorders, alcoholism, and personality disorders all independently 
contributed to poor social adjustment. Of those who were employed, almost half (43%) 
were on sick-leave. Besides severity and number of episodes of depression, female gender 
and age over 50 years strongly and independently predicted being on sick-leave. 
Factors influencing social and occupational disability and social adjustment among patients 
with MDD were studied prospectively during an 18-month follow-up period. Patients’ 
functional disability and social adjustment were alleviated during the follow-up concurrently 
with recovery from depression. The current level of functioning and social adjustment of a 
patient with depression was predicted by severity of depression, recurrence before baseline 
and during follow-up, lack of full remission, and time spent depressed. Comorbid 
psychiatric disorders, personality traits (neuroticism), and perceived social support also had 
a significant influence. 
During the 18-month follow-up period, of the 269, 13 (5%) patients switched to bipolar 
disorder, and 58 (20%) dropped out. Of the 198, 186 (94%) patients were at baseline not 
pensioned, and they were investigated. Of them, 21 were granted a disability pension during 
the follow-up. Those who received a pension were significantly older, more seldom had 
vocational education, and were more often on sick-leave than those not pensioned, but did 
not differ with regard to any other sociodemographic or clinical factors. 
Patients with MDD received mostly adequate antidepressant treatment, but problems existed 
in treatment intensity and monitoring. It is challenging to find those at greatest risk for 
disability and to provide them adequate and efficacious treatment. This includes great 
challenges to the whole society to provide sufficient resources. 
Keywords: major depressive disorder, record-based study, prospective study, social 
adjustment, social and occupational disability, quality of care, disability pension 
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3. INTRODUCTION 
Major depressive disorder (MDD) is one of the worlds’ most common mental disorders. 
About 6% of the Finnish population is suffering from it, and from milder depressive 
symptoms many times more. Patients suffering from MDD have several symptoms 
including either depressive mood or loss of interest or pleasure, difficulties in sleeping, 
fatigue or loss of energy, feelings of worthlessness or excessive or inappropriate guilt, 
diminished ability to think or concentrate or make decisions, and thoughts of death or 
suicide attempts. Depression has a strong tendency towards recurrence and chronicity. 
The Global Burden of Disease Study estimated in the 1990’s that MDD is worldwide 
the fourth leading cause of functional impairment, disability, and days lost from work 
(Murray and Lopez, 1997a). Depending on the different statistical conventions in 
developed vs. developing countries it is possible that many cases of depression have 
remained unrecognisable. Murray and Lopez (1997b) estimated that depression will be 
by the year 2020 the second major cause of functional disability. Patients with MDD 
have difficulties in physical, social, and role functioning. Even those suffering from 
relatively mild depressive symptoms appear to function significantly worse than do 
inpatients with several other chronic medical illnesses. Depression or depressive 
symptoms are also strongly associated with increased service utilisation and social 
morbidity (Johnson et al., 1992). The presence of comorbid somatic diseases or mental 
disorders leads to disability associated with depression. 
Effective MDD treatments have been available for decades. During the last 50 years 
effective medicines have been found and developed to treat depression. Different types 
of psychotherapy and electroconvulsive therapy have been in use far longer. There 
have, however, been repeated reports of severe problems in the availability, adequacy, 
intensity, and monitoring of treatment (Lehtinen et al., 1990b; Brugha & Bebbington, 
1992; Isometsä et al., 2000; Demyttenaere et al., 2004). 
As a cause of work disability, MDD has become increasingly more important. During 
the last decade in Finland (Salminen et al., 1997; Sorvaniemi et al., 2003; Karpansalo et 
al., 2005) much attention has been paid to work disability pensions granted for 
depression. The number of pensions has increased threefold in Finland between the 
1987 and 1994 (Salminen et al., 1997). These numbers include both permanent and 
temporary pensions, and some patients may return to work after temporary pensions. 
The increase in pensions has been remarkable, despite the creation of new, effective 
medicines with a favourable side-effect profile and the development of new 
psychotherapy strategies. Studies related to increased disability and number of pensions 
have not for the present been able to scrutinise these problems thoroughly. 
The present thesis includes a record-based and a prospective study in which treatment 
received and predictors affecting social adjustment and functional and work disability 
could be examined. 
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4. REVIEW OF THE LITERATURE 
4.1 Major depressive disorder (MDD) 
4.1.1 Definition of depression 
Depressive affects belong to normal human life. These can be seen as a normal response 
to an unpleasant event or situation or to a psychological or concrete loss. Normal 
lowered mood usually does not markedly affect one’s functional, social, or occupational 
ability or social adjustment. More severe depressive symptoms and disorders can be 
seen as a continuum from those normal feelings. Mood disorders are either unipolar 
(depressive disorder, dysthymia) or bipolar (bipolar affective disorder, cyclothymia) 
which are defined by given criteria. Even though strict boundaries between normal 
affect and depressive disorder do not exist, diagnosed disorders have a similar course, 
risks, and outcome. The differential diagnosis of unipolar - bipolar is an important one, 
as the course and treatment of bipolar affective disorder differ significantly from those 
of unipolar depression. 
4.1.2 Diagnosis of depression 
In diagnostic classifications, mood disorders are defined as “illnesses characterised by a 
distinct constellation of several co-occurring symptoms for a defined period of time 
contributing to significant psychosocial impairment” (WHO 1992; 1993; APA 1987; 
1994).
The ICD-10 classification of mental and behavioural disorders: clinical descriptions and 
diagnostic guidelines (WHO 1992; 1993) are in use in Finland. Diagnosis of a major 
depressive episode (MDE) in both classifications requires a 2-week period of at least 
one of the symptoms either 1) depressive mood or 2) loss of interest or pleasure. In the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), which 
has been used in this thesis, these must be accompanied by at least four (i.e., a total of at 
least five vs. ICD-10 requires symptoms totalling at least four) associated with 
symptoms existing nearly every day, such as 3) significant weight change (loss or gain), 
4) insomnia or hypersomnia, 5) psychomotor agitation or retardation, 6) fatigue or loss 
of energy, 7) feelings of worthlessness or excessive or inappropriate guilt, 8) 
diminished ability to think or concentrate or make decisions, and 9) suicidal thinking, 
recurrent suicidal ideation with or without a specific plan for committing suicide. 
These symptoms do not meet criteria for a mixed episode of the bipolar disorder. The 
symptoms cause clinically significant distress or impairment in important areas of 
functioning, and are not caused by physiological effects of a medication or an illness. 
The symptoms are not caused by loss of an important loved one (The ICD-10 does not 
exclude this), they last longer than two months or include obvious functional 
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impairment, feelings of worthlessness, suicidal thoughts, psychotic symptoms, or 
psychomotor retardation (APA, 1987; 1994). The MDD diagnosis includes one or more 
MDEs which are not accounted for by schizophrenia or schizophrenia, or other 
psychotic disorders, and there has never been a manic, mixed, or hypomanic episode. 
The DSM-IV also lists three levels of severity of MDD. Severity may be mild, 
moderate or severe (with or without psychotic features) based on the number and 
severity of the diagnostic criteria, and the degree of functional disability and distress. 
Psychotic MDE includes delusions or hallucinations, whether the psychotic features are 
mood congruent or mood incongruent. Depression can also include a few depressive 
symptoms diagnosed as minor depressive disorder (MinD). Those patients have never 
met the criteria of MDE or manic episode (DSM-IV). 
4.2 Epidemiology of MDD 
4.2.1 Incidence of MDD 
Although the epidemiology of depression has been studied widely, studies regarding 
incidence of depression have remained quite few. The two recent epidemiological 
studies in Finland, the Finnish Uusikaupunki – Kemijärvi study (UKKI study; Lehtinen 
et al., 1996)) and the Finnish sub-sample of the European Outcomes of Depression 
International Network study (ODIN) (Lehtinen et al., 2005) differ significantly by their 
methods and results. The first-mentioned study consists of populations randomly drawn 
from two small Finnish areas, southern and northern, and the second one of populations 
randomly drawn from two large southern urban (Turku) and rural (Koski tl, Marttila 
and Tarvasjoki) areas. Studies differed also from each other in with their diagnostic 
tools and diagnostic classifications. In the UKKI study, the annual incidence of neurotic 
depression was calculated as 2.0 per 1000 in men and 2.7 per women for the whole 16-
year follow-up period (Lehtinen et al., 1996). The ODIN study comprised 2999 
inhabitants aged 18 to 64. In this study, the annual incidence for the first-time episode 
of depressive disorder (according to ICD-10) was 20.5 per 1000 and recurrent episodes 
8.0 per 1000. Significant differences between results of these studies may be explained 
by the differences in their methods. 
4.2.2 Prevalence of MDD 
In contrast to studies concerning incidence of depression, several studies estimate the 
prevalence of depressive disorders in the general population. Those indicate that 
depression is a highly prevalent disorder (Kessler et al 1994; 2005), with a recurrent or 
chronic course, and often characterised by comorbidity with Axis I or II disorders or 
other somatic illnesses. Estimates are that as much as one-fifth of the population 
(Kessler et al 1994; 2003) will suffer from clinical MDE at some point in their lives. 
Depression seems to be more common in women than in men, and its recurrence rate 
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has been estimated as up to 60 to 87% (Mueller et al., 1999; Keller & Boland, 1998) 
depending on follow-up time. 
Variation in the prevalence of mood disorders (including bipolar I and II disorders, 
dysthymia, and major depressive disorder) has been estimated as quite small among 
developed countries, but greater between the developed and less-developed countries 
(Demyttenaere et al. 2004). Differences in resources in treatment and possible 
validation problems in diagnostic methodology may explain some part of this. 
In the USA, the National Comorbidity Survey Replication has estimated that in adults 
the lifetime prevalence of unipolar major depression in the general population is 16.2%, 
and the 12-month prevalence 6.6 to 6.7% (Kessler et al., 2003; 2005). The 
comprehensive National Epidemiologic Survey on Alcoholism and Related Conditions 
was conducted from 2001 through 2002 by the National Institute on Alcohol Abuse and 
Alcoholism (Bethesda, MD) in the USA (including Alaska and Hawaii) (Hasin et al. 
2005). The target population was the civilian, non-institutionalised population aged 18 
years and older. This study comprised 43 093 respondents in face-to-face interviews. 
The prevalence of 12-month DSM-IV MDD was 5.28% and lifetime 13.23%. In 
Australia, Andrews et al. (2001) found, in their study comprising non-institutionalised 
adults aged 18 or older, nearly the same proportion as in the USA, depending on the 
diagnostic system used (ICD-10, 6.7%; DSM-IV, 6.3%). 
Several European studies have estimated the epidemiology of MDD in their countries, 
showing prevalences of depression quite similar to those in the USA and Australia. In 
the Netherlands Mental Health Survey and Incidence Study (NEMESIS; Bijl et al., 
1998) in 1996, the prevalence of psychiatric disorders in the Dutch population aged 18-
64 found (by interviewing 7076 members of the general population) a lifetime MDD 
prevalence of 15.4% (in women 20.1% and men 10.9%) and a 12-month prevalence of 
5.8% (7.5% and 4.1%) (Bijl et al 1998). The European Study of the Epidemiology of 
Mental Disorders (ESEMeD), conducted between January 2001 and August 2003 in a 
non-institutionalised population in Belgium, France, Germany, Italy, the Netherlands, 
and Spain aged 18 or older (n=21 425), described the 12-month and lifetime prevalence 
rates of mood, anxiety, and alcohol disorders. In this comprehensive study, lifetime 
prevalence of MDD was around 13% and the 12-month around 4% (Alonso et al. 
2004a).
In Finland, the Mini-Finland Health Survey, an extensive epidemiological study of the 
Finnish population aged 30 years and over, conducted from 1978 through 1980 
(Lehtinen et al. 1990a) found in their large sample of the Finnish population aged 30 or 
more (n=8000) a one-month prevalence of 4.6% for neurotic depression. Another study 
comprising a total of 2293 of the Finnish general population in 1994 with a telephone 
survey and utilising the UM-CIDI Short Form found a 6-month prevalence of major 
depressive episode of 4.1% (Isometsä et al. 1997). The national Finnish Health Care 
Survey (FINHCS ‘96) monitored the health of the general population and evaluated the 
use of and need for health services. The data were collected between April 5 and June 
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21, 1996 from non-institutionalized Finnish individuals aged 15 to 75 (N=5993) by 
interviewing personally the reference person and other household members aged 15 and 
over. The 12-month prevalence of MDE was 9.3%, and the age-adjusted prevalences for 
females and males were 10.9% and 7.2%. After adjustment for age, factors associated 
with MDE were urban residency, smoking, alcohol intoxication, and chronic medical 
conditions (Lindeman et al. 2000). 
The most recent epidemiological, comprehensive, and multidisciplinary study in 
Finland, the Health 2000, interviewed a representative sample (6005) of the Finnish 
general adult population (? 30 years), in the period 2000–2001 with the CIDI for the 
presence of DSM-IV mental disorders during the last 12 months. MDD prevalence was 
4.9% (males 3.4%, females 6.3%) and any depressive disorder 6.5% (4.5% and 8.2%). 
In the Health 2000 study, depressive disorders were most usual in the middle-aged, in 
residents of the Oulu region, among men separated or divorced, and among the 
unemployed (Pirkola et al., 2005). Differences between the prevalence figures may be 
explained by differences in the diagnostic tools used (in the former study UM-CIDI SF 
vs. CIDI in the latter). 
In conclusion, prevalence of depression seems to be fairly comparable in western 
industrialised countries. Differences in prevalences between males and females seem to 
hold, while taking into account design, sampling, and other methodological differences 
between studies.
4.2.3 Use of health care services for MDD 
The high burden of depression makes great demands upon the mental health services 
provided. Although effective treatments exist, treatment-related studies have shown that 
many patients with MDD remain untreated or undertreated (Demyttenaere et al. 2004; 
Shen et al. 2006). The big question is: Has the patient any contact with the health 
service system, and if so, what kind of treatment is that patient receiving? The median 
treatment gap has, among psychiatric disorders, been found to be one of the greatest for 
depression (56.3%; Kohn et al. 2004). 
The ESEMeD project (Alonso J et al. 2004b) found that only 36.5% of patients with 
mood disorders had consulted formal health services. The Mini-Finland Health Survey 
(Lehtinen et al. 1990b) assessed, besides the epidemiology of diseases and disorders, 
also the met and unmet need for mental health care. In this comprehensive study, about 
60% of those patients in need of care received no treatment, and half the treatment 
received was inadequate. Of the depressive subjects, only one-third received some kind 
of treatment. Two of five suffering even the most severe MDE did not use the health 
services for depression. However, the more severe, long-lasting, and disabilitating the 
depression, the more probable was the use of health services for major depression 
(Hämäläinen et al., 2004). 
Patients seeking treatment have problems in recognizing their depression. Vuorilehto et 
al. (2005) reported that only one-third of the depressed primary care patients perceived 
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a need for treatment for psychological reasons. The Finnish Health Care Survey, 
conducted in 1996 and consisting of a random population sample of 5993 Finns aged 15 
to 75 years, found that only 13% of subjects suffering from MDE reported use of 
antidepressants during the preceding 12 months. 
4.3 Aetiology of MDD 
Depression is an etiologically complex disorder influenced by risk factors from multiple 
domains that are interrelated through developmental pathways (Kendler et al. 1993; 
2003; 2006b). The main domains of risk factors associated with the development of 
depression are, basically, genetic, biological, developmental, and environmental (Caspi 
et al. 2003; Kendler et al. 2001; 2002; 2004; 2006b). By these means, development of 
depression is likely mediated by the interaction of genetic and environmental factors. 
4.3.1 Heritability of MDD 
MDD is inevitably a familial disorder (Lieb et al., 2002; Weissman et al., 2005) and its 
familiality results mostly or entirely from genetic influences (Sullivan et al., 2000). In 
family studies it is impossible to distinguish genetic influences from environmental risk 
factors, which also are familial. However, the current literature has estimated that 
heritability of depression is lower than that of schizophrenia or alcoholism (True et al., 
1996; Kendler et al., 1992). Studies have reported different estimates of depression 
heritability, percentages usually ranging between 20 and 45% (Sullivan et al., 2000; 
Kendler et al., 2002; 2004; 2006b), but higher have also been reported (54-70%) 
(Torgersen, 1986; Lesch, 2004). Sullivan et al (2000) reported in their meta-analysis 
strong evidence for an association between major depression in the proband and major 
depression in first-degree relatives. Although several epidemiological studies have 
demonstrated a clear environmental component in the aetiology of MDD, especially 
twin studies have demonstrated the presence of genetic factors. Kendler et al. (2006a) 
demonstrated that the heritability of major depression is higher in women than in men 
and that some genetic risk factors for major depression are gender-specific in their 
effect.
Recent genetic studies have identified genetic markers that may indicate susceptibility 
to depressive disorders. Monoamine transporter genetic variation has been found to 
have linkage and association with psychiatric and other complex disorders (Hahn & 
Blakely, 2002). It has been suggested that this polymorphism, especially in the 
promoter region of the serotonin transporter (5-HTT) gene, also is related to stress 
vulnerability (Caspi et al. 2003). Other studies of depression neurobiology hypothesise 
that neurotoxic effects of hypercortisolemia may damage hippocampal cells, 
contributing to depression. Supporting this, Sheline et al. (2003) showed that 
hippocampal volume was significantly predicted by duration of untreated depression, 
whereas no relationship was detectable between cumulative time treated with 
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antidepressants during depression. They suggested that antidepressants may have a 
neuroprotective effect during depression. Hippocampal volume loss during untreated 
depression has been thought to be mediated by deficient function of neuroprotective 
peptides. Genetic factors may underlie this, acting by altering the balance of neurotoxic 
and neuroprotective responses to stress. Antidepressants have been shown to enhance 
neuroprotective effects (Manji et al., 2001; Castrén, 2005) in animal experiments. 
4.3.2 Developmental and psychosocial factors 
Genetic factors explain a great part of the entire aetiology of MDD. It is undoubtedly a 
clinically heterogeneous disorder thought to result from multiple genes interacting with 
environmental and developmental components modifying  the patient’s mental state. 
Such would be: maternal stress during pregnancy (Essex et al., 2002; O’Connor et al., 
2002; Oates, 2002), parental depression (Lieb et al., 2002), traumatic childhood 
experiences (Tennant, 1988; Heim et al., 2000), predisposing comorbidity (Caspi et al., 
1996; Young et al., 2004), lack of social support from family or friends, or stressful life 
events (Brown & Harris, 1978; Miller et al., 1986; Cooper & Paykel, 1994; Paykel et 
al., 1969; Kendler et al., 2004). Stressful life events with a combination of humiliation 
and loss, which directly devaluate the individual, are clearly depressogenic (Kendler et 
al., 2003). However, especially in women, emotionally supportive social relationships 
seem to have a protective effect against depression (Kendler et al. 2005). Neuroticism 
has been shown to modify the risk for depressive episodes in the context of stressful life 
events (Kendler et al. 2004). Kendler et al. (2002) constructed a developmental model 
to predict depressive episodes in the year before the most recent interview. They 
considered eighteen risk factors in five developmental tiers: firstly, childhood traumas 
and genetic factors, secondly, personality development in early adolescence, thirdly, 
possible traumas, substance abuse, and other factors in late adolescence fourthly, 
adulthood traumas and major depression history, and fifthly, difficulties during the last 
year.
4.3.3 Hormonal, neurochemical, physiological and structural 
findings in depression 
Hormonal changes have a clear connection with major depression (Birzniece et al., 
2006; Keller et al., 2006; Young & Veldhuis 2006; Young et al., 2000). The 
hypothalamic-pituitary-adrenal (HPA) system is an important factor as a stress-
responsive system. In stressful events, the HPA axis is activated, and the hypothalamus 
secretes the corticotropin-releasing hormone (CRH), which causes increased 
corticotropin release in the pituitary. Corticotropin stimulates in the adrenal cortex the 
production and release of cortisol, which is the adrenal glucocorticoid stress hormone 
secreted in humans. The production and release of hypothalamic CRH and corticotropin 
are regulated by the circulating glucocorticoids through negative feedback loops to the 
hypothalamus and pituitary. Enhanced cortisol activity is related to depression, its 
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severity, and the interaction of depressive and psychotic symptoms (Arborelius et al., 
1999; Sapolsky, 2000; Keller et al., 2006). 
The cytokines have been suggested to play an important role in the mediation of the 
pathophysiological characteristics of major depression (Maes 1995). This model implies 
that MDD is related to activation of the inflammatory response system. In the 
depressive disorders, one of the actions of the cytokines may be that they cause HPA 
axis hyperactivity (Schiepers et al. 2005). 
The newest studies support the network hypothesis of depression, which is based on the 
dynamics of the central nervous system (Hua & Smith, 2004¸ Buzsaki, 2004). These 
networks are thought to develop through interactions with the environment, and the 
neuronal structure of and neurotransmission in these networks are constantly being 
refined through activity-dependent synaptic plasticity to optimally process and store 
relevant information (Katz & Shanz, 1996; Castrén, 2005). The best support for this 
network hypothesis is the recent observation that long-lasting antidepressant treatment 
leads to increased production of new neurons in the rat hippocampus (Malberg et al., 
2000). On the other hand depression duration predicts hippocampal volume-loss in 
women with recurrent depression. This loss may be the cause of cognitive impairment 
in these patients (Sheline et al., 1999). Goldapple et al. (2004) showed that in patients 
treated with cognitive behaviour therapy (CBT) the treatment response was associated 
with significant metabolic changes: increases in the hippocampus and dorsal cingulate 
and decreases in the dorsal, ventral, and medial frontal cortex. These changes were 
associated with patients’ clinical recovery by their modulation of the functioning of 
specific sites in limbic and cortical regions. As these changes were distinct from those 
found after paroxetine treatment, they therefore concluded that like other antidepressant 
treatments, CBT seems to affect clinical recovery by modulating the functioning of 
specific sites in limbic and cortical regions. Unique directional changes in frontal 
cortex, cingulate, and hippocampus with CBT relative to paroxetine may reflect 
modality-specific effects with implications for understanding mechanisms underlying 
different treatment strategies. 
Most recently, changes in depressive patients vs. healthy controls have been observed in 
magnetoencephalography (Linkenkaer-Hansen et al., 2005), and EEG changes in 
depressive patients have been found (Fingelkurts et al., Published Online: 15 Jun 2006). 
Both findings are possibly linked to the findings of the abnormal structural changes 
(Campbell et al. 2004; Lloyd et al. 2004; Milak et al. 2005; Neumeister et al., 2005; 
Videbech et al., 2004) in MDD. 
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4.4 Course and outcome of MDE 
4.4.1 Duration of MDE and course of MDD 
Data on the duration of MDE differs notably among studies, mostly dependent on the 
population studied. Eaton et al. (1997) calculated its duration in the general population 
in the Epidemiological Catchment Area Study (ECA) as about 12 weeks and also 
estimated that the duration of the first episode was longer than that of recurrent 
episodes. Spijker et al. (2002) observed the median of depression duration as nearly the 
same; meanwhile, Hämäläinen et al. (2004) estimated the length of the depression 
episode depending on severity as 4, 5, or 9 weeks. Kessler et al. (2003) estimated the 
episode length to be 16 weeks. Hasin et al. (2005) reported the median episode length to 
be 24.3 weeks in the general population in the USA. This variation in results may be 
explained by the different definitions of the episode. Studies indicate that in psychiatric 
care MDE endures longer (Solomon et al., 1997; Melartin et al. 2004). 
Depression is a life-long, recurrent, and disabling disorder. The high recurrence rate and 
a tendency towards chronicity have been demonstrated strongly. Even during the two-
year follow-up after their first MDE, about one third suffer at least one more. During 
five years nearly 60%, during 10 years about three-fourths, and after 15 to 25 years 
about 85% (Angst 1986; Brodaty et al. 2001; Keller & Boland, 1998; Mueller et al 
1999) suffer at least one more episode. Subsyndromal, minor depression, or dysthymia 
dominate the course of unipolar MDD (Judd et al. 1998). Because of the chronic course 
of depression disability is pervasive and increases with the increment of the symptom 
severity. During the recovery from MDE disability decreases (Mintz et al., 1992) or 
disappears (Judd et al., 2000a) but it seems clear that after a severe recurrent episode 
disability does not return to its premorbid level after depression remission (Ormel et al. 
2004).
4.5 Comorbidity of MDD 
Axis I and II comorbid diagnoses may be difficult to make accurately in depressed 
patients, who may unconsciously exaggerate their symptoms or feelings and thus fulfil 
the criteria of some other mental disorder that, when in remission, they do not suffer 
from. 
4.5.1 Axis I comorbidity in MDD 
Comorbidity in depression has been widely studied. Patients suffering from unipolar 
depression usually have at least one comorbid Axis I disorder (Placidi et al., 2000; 
Melartin et al., 2002; 2004; Merikangas et al., 2003; Alonso et al., 2004c; Hasin et al., 
2005; Vuorilehto et al., 2005). The frequency of comorbid disorders depends on the 
population studied. About 50% of primary-care MDD patients suffer from anxiety 
Lopullinen.pdf   27 14.9.2006   10:36:26
28
disorders (social and simple phobias 23%, panic disorder 9%, generalised anxiety 
disorder (GAD) 20%, and other anxiety disorders 8%), those with alcohol or substance-
use disorder had 16% (Vuorilehto et al., 2005). Alcohol-use disorders (Melartin et al., 
2002; Hasin et al., 2005; Vuorilehto et al., 2005) are relatively usual. The frequency of 
MDD in dysthymic patients (double depression clinical populations ) is about 12% 
(Melartin et al., 2002; Vuorilehto et al., 2005). 
4.5.2 Axis II comorbidity in MDD 
Frequently the question has been: Is it possible to assess personality disorders 
simultaneously when a patient is depressed (Stuart et al. 1992)? In diagnostic 
classification this has been considered possible (DSM-IV, Multiaxial Evaluation). Only 
a few studies have assessed both depression and Axis II disorders in the same 
population (Sato et al., 1996; Melartin et al., 2002; Hasin et al., 2005). The most usual 
personality disorders in depression seem to be avoidant, borderline, and paranoid 
personality disorder (Melartin et al., 2002; Markowitz et al., 2005). As a personality 
trait, neuroticism (Eysenck & Eysenck, 1964) has been strongly connected with MDD 
(Lyness et al., 1998; Mulder, 2002; Kendler et al., 2004). 
4.5.3 Axis III comorbidity in MDD 
In depressive patients, somatic diseases are common (Katon & Sullivan, 1990; Isometsä 
et al., 2000; Vuorilehto et al., 2005), often chronic ones (Moldin et al. 1993; Oslin et al., 
2002). Of primary care MDD patients, 47% have been found to suffer from chronic 
medical illnesses (Vuorilehto et al., 2005). 
4.6 Treatment of MDD 
Effective treatments of depression, such as antidepressants, different psychotherapies, 
ECT, and combinations of these, have been in use for decades. Despite the treatments 
available, problems have been reported in the treatment provided and its efficacy all 
over the world (Lehtinen et al. 1990b; Brugha & Bebbington, 1992; Salminen et al., 
1999; Laukkala et al., 2001; Kohn et al., 2004; Starkes et al., 2005; Wittchen & Jacobi, 
2005; Shen et al., 2006). For this reason there have been developed several treatment 
guidelines to improve treatment of depression (APA 1993; 2000; Schulberg et al., 1998; 
Bauer et al., 2002; NICE, 2004; Depressio: Käypä hoito -suositus, 2004).
4.6.1 Psychosocial treatment 
The several psychotherapy types in use in the treatment and rehabilitation of depression 
are cognitive-behavioural approaches, brief, interpersonal therapy, structured 
psychodynamic short-term therapy, and psychodynamic therapy. Psychotherapy even 
alone is recommended for mild to moderate depression (APA, 2000; Depressio: Käypä 
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hoito-suositus, 2004). The outcome of psychotherapeutic treatment is influenced both 
by factors specific for each type of psychotherapy and by unspecific factors. A typical 
therapy visit lasts 45 minutes. Time-limited psychotherapies involve a variable number 
of therapy sessions; usually the number ranges from a few to up to 20 to 30 weekly 
sessions. In brief therapies, 10 to 20 weekly therapy sessions usually are sufficient. 
Long-term individual therapies typically involve from one up to three weekly sessions 
lasting from one to several years. Research on the efficacy of the different 
psychotherapy types has focused on time-limited therapies. The lack of several 
randomised, controlled clinical trials of long-term cognitive or psychodynamic 
psychotherapies, or of psychoanalysis makes it difficult to estimate their effectiveness 
in the treatment of depression (Isometsä et al., 2003). 
4.6.2 Antidepressant treatment 
Modern effective antidepressants have been in use since 1957 (Ban, 2001), and since 
then the development of new antidepressants has been intensely based on the 
monoamine theory. The four main types of antidepressants are serotonin reuptake 
inhibitors, noradrenaline reuptake inhibitors, serotonin and noradrenaline reuptake 
inhibitors, and monoamine oxidase inhibitors. Antidepressant treatment of MDD 
consists of three phases: an acute, a continuation, and a maintenance phase. 
4.6.2.1 Acute phase treatment 
Acute phase pharmacotherapy is effective for all severities of MDE. In mild to 
moderate depression, psychotherapy alone or combined with medication is helpful. 
While medication is part of the treatment, it must be integrated with the psychiatric 
management and any other treatments provided. The more severe the depression, the 
more important is the role of adequate medication. All antidepressants available are 
shown to be equally effective, and differences are mostly related to their adverse 
effects. The dosage of the antidepressant must be adequate as defined in the treatment 
guidelines (APA 1993; 2000; Depressio: Käypä hoito -suositus, 2004) (Table 1.). The 
goal of the treatment is always full remission in order to restore the patient’s functional 
ability and prevent relapses (Judd et al., 2000b; Papakostas et al., 2004; Pintor et al., 
2004).
4.6.2.2 Continuation phase treatment 
When the full remission has been attained, antidepressant treatment has to continue at 
its full dosage from 4 to 9 consecutive months. After sustained remission the need 
should be considered for maintenance treatment to prevent more relapses or 
recurrences. (APA 1993; 2000; Depressio: Käypä hoito -suositus, 2004). 
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4.6.2.3 Maintenance phase treatment 
Antidepressant treatment clearly reduces the risk for relapse in depressive disorder, and 
many patients with recurrent depressive disorder will benefit from continued treatment 
with antidepressants. The treatment benefit for an individual patient will depend on his 
or her absolute risk for relapse, with greater benefits for those at higher risk. 
Maintenance treatment should be considered if a patient has a third at least moderate 
depression episode, has had comorbid conditions, residual symptoms between episodes, 
severe disability, suicidal behaviour or psychotic features. Nearly the same treatment 
(antidepressant at full dose, psychotherapy perhaps at a lowered frequency) that was 
effective during acute depression and should continue preferably for years to prevent 
further recurrences (APA 2000; Geddes et al., 2003; Depressio: Käypä hoito-suositus, 
2004).
Table 1. Antidepressants available in Finland in 2006. Based on Duodecim, Käypä 
hoito, 2004, and updated with a new antidepressant. 
Generic name Starting dose Usual dose 
 (mg/day) (mg/day) 
Tricyclics (TCA)  
 amitriptyline 25.– 50 75.- 300 
 clomipramine 25.– 50 75.- 300 
 doxepin 25.– 50 75.- 300 
 nortriptyline 25.– 50 50.- 200 
 trimipramine 25.– 30 75.- 300 
Selective serotonin reuptake inhibitors (SSRI)  
 citalopram 20. 20.- 60 
 escitalopram 10. 10.- 20 
 fluoxetine 20. 20.- 80 
 fluvoxamine 50. 100.- 300 
 paroxetine 20. 20.- 50 
 sertraline 50. 50.- 200 
Other antidepressants 
 duloxetine 60. 60.
 mianserin 30. 30.- 120 
 milnacipran 50. 100.
 mirtazapine 15.– 30 30.- 60 
 moclobemide 300. 300.- 900 
 reboxetine 8. 8.- 10 
 trazodone 50.– 100 150.- 500 
 venlafaxine 75. 75.- 375 
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4.6.3 Electroconvulsive therapy (ECT) 
Electroconvulsive therapy is the oldest modern treatment of depression. It has been in 
use since the late 1930’s, first as treatment for psychoses. Its action has not been 
entirely understood, but different hypotheses exist, such as HPA axis normalisation 
(Yuuki et al., 2005). It is an effective short-term treatment for depression and is 
probably more effective than drug therapy. Bilateral ECT is moderately more effective 
than unilateral ECT, and high-dose ECT is more effective than low-dose ECT (The UK 
ECT review group, 2003). ECT should be considered if antidepressants fail to resolve 
depression, in patients with a high severity of symptoms, or those who are suicidal, or 
have other life-threatening symptoms, or when antidepressant treatment is precluded 
because of somatic illness (APA, 2000; Depressio: Käypä hoito-suositus, 2004). 
4.6.4 Treatment of refractory depression 
Combined treatment by psychotherapy and pharmacotherapy is associated with better 
outcome than is either treatment alone (Hirschfeld et al., 2002; Pampallona et al., 2004). 
Antidepressant combination may be more favourable in some cases than is one drug 
alone (Nelson et al., 1991; Nutt, 2002). Combining of drugs is intended to combine 
mechanisms of action, not just of drugs to promote pharmacological synergy and 
tolerability and to use important synergies within the serotonin, noradrenaline, or even 
dopamine monoaminergic system. In refractory depressions, whereas two consecutive 
antidepressant trials have not been favourable at adequate doses and durations, 
combination or augmentation strategies may be effective. The usual augmentation 
agents are lithium (Dinan & Barry, 1989), buspirone (Appelberg et al., 2001) and 
triiodothyronine (Lifschytz et al. 2004). Antidepressants combined with neuroleptics are 
needed in psychotic depression (Depressio: Käypä hoito-suositus, 2004). ECT 
combined with antidepressant therapy may be useful in patients with severe depression 
(Hirschfeld, 1999).
4.7 Disability 
4.7.1 Functional and work disability 
Functional disability has been defined as limitations in performing social and family 
roles and tasks (Nagi, 1976), or restricted ability to perform the most basic activities. 
Lack of social adjustment is a part of functional disability. Problems in it may seem to 
be difficulties in the patient’s role performance, interpersonal relationships, and work 
and leisure satisfaction (Weissman & Bothwell, 1976). Work disability is a specific 
form of impairment, defined as inability to work at a job or business, and receiving 
social security benefits or disability pension on that basis (MMWR, 2000). 
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4.7.1.1 Functional disability in MDD 
Disability associated with unipolar MDD is pervasive, affecting most areas of everyday 
life, and varying as a function of depressive symptom severity. The level of disability 
seems to correspond to the level of depressive symptomatology, and decreases (Mintz et 
al., 1992) or disappears (Judd et al., 2000a) when the patient is asymptomatic. It is 
unclear how simultaneously occur the recovery from depression and the disappearance 
of disability symptoms. This is a problem worth further research. Persons with major 
depression are at an almost five times greater risk for disability than are the 
asymptomatic (Broadhead et al., 1990). 
4.7.1.2 Work disability in MDD 
Work disability may appear both as decreased ability to work or as days lost from work, 
and unipolar depression is its fourth leading cause worldwide (Murray & Lopez, 1997). 
Even diminished ability to work affects work productivity considerably. Depression 
itself causes severe human suffering to the individual and leads to reduced performance 
while at work and work absence, both causing enormous costs to the employee, 
employer, and to society, as lack of income. Additional to this are costs of the treatment 
of depression, with costs being the higher the more severe the depression (Simon, 
2003). Improvement of depression is associated with the possibility that patients are 
able to maintain their paid employment. Their treatment costs also diminish some in the 
future (Simon et al., 2000). 
4.7.1.3 Work disability pensions due to MDD 
Depression is the most prevalent mental disorder causing sickness absence from work 
(Wells et al., 1989; Hensing et al., 2000), and the increasing number of disability 
pensions granted for major depression is a major concern. During the last two decades, 
especially in Finland, new disability pensions granted due to mental disorders have 
increased markedly, including both permanent and temporary pensions (Salminen et al., 
1997, Finnish Centre for Pensions, 2006; Figure 1). Nearly half the disability in 2005 
received their pension due to mental disorders (Figure 2), and over three-fifths of those 
granted a new disability pension due to mental disorders in 2005 received it due to 
mood disorders (Figure 3). 
Predictive factors for being granted a disability pension have been examined in a few 
studies, despite depression’s human and economic significance. Salminen et al. (1997) 
hypothesised that the deep economic recession in the early 1990’s, changes in the 
diagnostic system, and better recognition of affective disorders may be factors 
contributing to this development. Isometsä et al. (2000) found in their study of a 
random representative sample of 277 subjects drawn from the Disability Pension 
Register of the Social Insurance Institution that comorbid mental or physical disorders 
had the most significant effect on being granted a disability pension Sorvaniemi et al. 
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(2003) found, in their retrospective document-based cohort study of 213 adult 
psychiatricoutpatients, that greater age, comorbidity, and lowered self-esteem were 
strongly associated with being granted a pension. It is notable that only a few in this 
study received adequate antidepressant treatment.These studies were done by quite 
different methods, and a comprehensive, prospective, naturalistic cohort study focusing 
on the whole comorbidity, social, functional and work disability is lacking. 
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Figure 2. All disability pensions in 2005 due to mental disorders in the private sector. 
Source of information: Finnish Centre for Pensions, 2006 (F20-F29 Psychoses, F30-F33 
Mood disorders). 
29 %
25 %
46 %
F20-F29
F30-F33
Other
Figure 3. New work disability pensions granted in 2005 due to mental disorders in the 
Finnish private sector. Source of information: Finnish Centre for Pensions, 2006 (F20-
F29: Psychoses, F30-F33: Mood disorders). 
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61 %
25 %
F20-F29
F30-F33
Other
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4.7.1.4 Conclusions of the present literature 
Studies conducted in the 1980s (Keller et al., 1982; 1986; Kocsis et al., 1988; Brugha & 
Bebbington, 1992) showed that patients receiving no specific treatment for depression, 
or inadequate treatment, seemed to have been the rule, even among patients attending 
psychiatric facilities. Problems in the treatment of depression are closely connected to 
the patient’s level of disability; level of disability corresponds to the level of depressive 
symptomatology, and is alleviated when the patient is asymptomatic (Judd et al. 2000a). 
Some other studies have shown that disability recovery is slower than symptom 
remission (Mintz et al. 1992). 
Many cross-sectional studies have reported that MDD with comorbid mental disorders 
is associated with more impairment than is pure MDD alone (Isometsä et al. 2000; 
McDermut et al. 2001). The personality trait neuroticism (Lyness et al. 1998) and poor 
social support (Hays et al. 2001), seem to be associated with functional disability 
among older adults with MDD. Among patients of working age, poor family 
functioning (Keitner and Miller, 1990) and low satisfaction with one’s social support 
(Ezquiaga et al. 1999) may predict a less favourable course of MDD. 
In Finland has been noticed during the last two decades a rapid increase in long-term 
work disability pensions due to depression. Salminen et al. (1997) noted the rapid 
increase in number of long-term work disability pensions, temporary and permanent, 
between 1987 and 1994, raising the issue how and why the functional capacity of 
depressive patients could have markedly deteriorated despite new drugs and other 
treatments that had become available. Isometsä et al. (2000) investigated in their 
representative record-based study has been investigated the quality and intensity of 
treatment provided for patients with clinically diagnosed depression who were granted a 
disability pension in Finland in 1993. 
On the basis of the present literature, current information on the intensity and quality of 
treatment is limited. Poor or insufficient treatment cannot influence recovery from 
depression and thus reduce disability, and factors associated with patients’ characteristic 
features are not well known. Another major issue little investigated is to what extent the 
present functioning of the patient reflects the patient’s present state, or includes the 
accumulated burden of the earlier illness history. Overall, given the high human and 
economic costs of long-term disability, continuous evaluation of quality of treatment 
provided to those disabled due to depression is warranted. 
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5. AIMS OF THE STUDY 
This study investigated the treatment received in a record-based study of 803 secondary 
care patients and predictors affecting psychosocial and work disability at baseline and 
during follow-up in the prospective part of the VDS consisting of 269 patients. This 
thesis consists of four original publications, the aims of which are: 
I To investigate the adequacy of the antidepressant and quality of the 
psychosocial treatment for depression in 1996 in a psychiatric secondary care 
setting providing treatment for a well-defined catchment area. 
II To investigate in the follow-up study baseline predictors of psychosocial 
disability and current work disability in a large sample of patients with MDD. 
III To prospectively investigate in our cohort of patients with MDD during the 18-
month follow-up predictors of functional and psychosocial disability. 
IV To prospectively investigate, during the 18-month follow-up, factors predicting 
long-term work disability resulting in work disability retirement among 
patients with MDD. 
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6. METHODS 
6.1 General study design 
The Vantaa Depression Study (VDS) is a collaborative depression research project in 
cooperation with the Department of Mental Health and Alcohol Research of the 
National Public Health Institute, Helsinki, Finland, and the Department of Psychiatry of 
the Peijas Medical Care District (PMCD), Vantaa, Finland. The catchment area of the 
project comprises the city of Vantaa (population 169 000 in 1997). The PMCD 
Department of Psychiatry offers secondary care psychiatric services to all Vantaa 
citizens. These include a psychiatric inpatient unit, a general hospital outpatient clinic, 
six community mental health care centres, and two day hospitals. 
6.2 Design of the record-based study (Study I) 
Data for this study were collected from a computerized patient database incorporating 
all outpatient visits as well as treatment periods at the inpatient unit. 
6.2.1 Inclusion criteria 
Inclusion criteria in this study incorporated all patients aged 20 to 59 years who had 
been assigned a clinical diagnosis of Depressive Episode (F32.xx) or Recurrent 
Depressive Disorder (F33.xx) according to the ICD-10, and who had at least one 
outpatient visit or day as an inpatient in the Peijas Medical Care District during the 
study period January 1, 1996, to December 31, 1996. 
6.2.2 Exclusion criteria 
We excluded all patients who had earlier received a diagnosis of schizophrenia, other 
non-affective psychosis, or bipolar disorder. Exclusion criteria also applied to patients 
treated in the somatic departments of Peijas hospital, or who had only consulted but 
were not treated by the psychiatric consultation services. 
6.2.3 Data collection 
In the computerized database were found 972 patients initially fulfiling inclusion 
criteria in the register of visits to outpatient clinics or hospital stays. In the patient 
records, 169 of these had diagnoses fulfiling the exclusion criteria, and the remaining 
803 patient records were examined thoroughly. A structured form with 57 items was 
filled in including a) sociodemographic and clinical characteristics of the patients, and 
b) treatment received during the whole treatment period in the PMCD, irrespective of 
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the year it began. Treatment provided was reviewed up to the end of 1997 if continued. 
Patients treated at the PMCD inpatient unit at least once were classified as inpatients. 
There were no possibilities to record Axis I and II comorbidity, except alcohol misuse, 
because only the first diagnosis was known. Diagnoses were clinical and were made by 
the treating psychiatrist according to the ICD-10. Possible alcohol misuse was noted if 
the patient him- or herself or the treating personnel considered it to be a problem. The 
number of antidepressant trials was calculated, and medicine combinations including 
both antidepressants and neuroleptics and augmentations were recorded. The adequacy 
of any antidepressant dose was defined as the usual adult dose in the APA Practice 
Guidelines (APA, 2000); the length of treatment with antidepressants and switching 
strategies for it were recorded. Changes in work disability and pensioning were 
analysed.
6.2.4 Validity of the diagnoses 
In the computerised database were all outpatient visits and hospital stays with first 
diagnosis found. From this database were selected those having at least once a ICD-10 
clinical diagnosis of F32.x or F33.x. The medical records ensured that each patient’s 
diagnosis fulfiled the criteria of MDE. Of the 972 eligible patients, 169 had an earlier or 
current diagnosis of schizophrenia, other non-affective psychosis, or bipolar disorder, 
and these were excluded. The severity of depression as classified in the clinical ICD-10 
diagnosis was shown in the database. Its validity in the beginning of the treatment 
period was estimated by selecting randomly 181 patients’ diagnoses, and the author 
estimated the severity based on the description of each patient’s status in the medical 
records. The author estimated 4.4% (8 of 181) of diagnoses differently than did the 
treating psychiatrist. Possible alcohol misuse was stated in the medical records either as 
the patient’s or health professional’s opinion or both. 
6.2.5 Outpatient visits and hospital stays 
All outpatient visits and hospital stays were found in the computerized database. All 
visits for the current episode were calculated; patients with at least one hospital stay 
during the current episode were treated as inpatients, and the lengths of the hospital 
stays were calculated. 
6.2.6 Sociodemographic characteristics and work status 
Patients’ age, gender, marital status, occupational status, and work status at both the 
beginning and at the end of the treatment period were recorded, and especially work 
disability pensions. 
6.2.7 Treatment received 
In the database and medical records were available all data including 
psychopharmacological treatment, number of visits to psychiatrists and other health 
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professionals, inpatient treatment, and acceptance or refusal of antidepressant treatment. 
All antidepressant treatment trials and their doses were recorded as well as the adequacy 
of the antidepressants received. Other medication, like neuroleptics, anxiolytics, 
hypnotics, and possible augmentation medications, were recorded, and use of 
electroconvulsive therapy was analysed. 
6.3 Design of the VDS cohort study (Studies II-IV) 
6.3.1 Patient screening 
In the first phase of the study, psychiatric patients were screened for the presence of 
depressive symptoms during a 16-month period starting from February first 1997. 
During that period, 806 patients were screened at the ages of 20 to 59 years if they 
were: 1) seeking treatment at the Department of Psychiatry, 2) being referred there, or 
3) already receiving care and now showing signs of deteriorating in their clinical state 
there, but without a clinical diagnosis of ICD-10 schizophrenia or bipolar I or II 
disorders. These were screened by the personnel for the presence of depressive 
symptoms. The screening instrument included the five screening questions for 
depression from the WHO Schedule for Clinical Assessment in Neuropsychiatry 
(SCAN), Version 2.0 (Wing et al., 1990). These questions were: 1. “Have you felt 
yourself depressed during the past month?” 2. “Have you often cried during the past 
month?” 3. “Do you no longer positively enjoy things usually felt to be enjoyable?” 4. 
The interviewer estimates possible “masked” depression, 5. “Have you thought of 
harming yourself?”. The final question was been specified by five additional questions 
according to the Scale for Suicidal Ideation (SSI) (Beck et al., 1979) to identify cases 
with moderate to severe suicidal ideation or plans. After either 1) a positive response to 
any of the SCAN screening questions or 2) a score of six or more on the SSI, 
irrespective of the presence of depressive symptoms, the patient was fully informed 
about the study project, and written informed consent requested. Of the 703 eligible 
patients, 161 (22.9%) refused to participate in the study, but 542 (77.1%) agreed and 
gave their written informed consent after the procedure was fully explained. Those 
refusing patients did not significantly differ from those participating in age or gender. 
The Ethics Committee of Peijas Hospital approved the study in December 1996. 
6.3.2 Diagnostic process 
All interviewers had received relevant training by a WHO-certified training centre on 
use of the SCAN, Version 2.0 (Wing et al., 1990) diagnostic tool. Patients were 
interviewed face-to-face by one of the researchers (U.L., P.L-M., T.M., H.R., or P.S.). 
They examined whether or not the current mood episode fulfiled the criteria for 
(unipolar) DSM-IV Major depressive disorder. All psychiatric and medical records in 
the PMCD, including a standardised set of laboratory tests, were also available at the 
interview. On this basis, all 269 patients diagnosed with DSM-IV MDD were included 
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in the MDD Cohort Study. Diagnostic reliability was found to be excellent (kappa for 
MDD 0.86 ?0.58-1.0?; Melartin et al., 2002). All patients included in the study cohort 
were interviewed with the entire SCAN to give a full picture of Axis I comorbid 
disorders, and with the Structured Clinical Interview for DSM-III-R personality 
disorders (SCID-II) (Spitzer et al., 1987) to assess diagnoses on Axis II. Current and 
past axis III diseases were assessed via a self-report checklist with 44 items 
(corresponding to ICD-10 diagnoses) and medical records. However, the study included 
only axis III diseases diagnosed by a physician and currently being treated. 
6.3.3 Exclusion criteria 
We excluded all patients who had earlier received a diagnosis of schizophrenia, other 
non-affective psychosis, or bipolar disorder even if they currently fulfiled MDE criteria. 
Currently alcohol-abusing patients with less than two to three weeks of abstinence were 
excluded.
6.3.4 Self-report and observer scales 
For assessment of the severity of MDE, the patient completed the 21-item Beck 
Depression Inventory (BDI; Beck et al., 1961) and as the observer scale we used the 17-
item Hamilton Rating Scale for Depression (Ham-D; Hamilton, 1960). Current 
functional disability was assessed by the Social and Occupational Functioning 
Assessment Scale of DSM-IV (SOFAS; Goldman et al., 1992) as an observer scale. 
This differs from the Global Assessment of Functioning (GAF; APA, 1987) in 
measuring purely the level of social and occupational functioning, without taking 
symptoms into account. Its validity has been found to be good (Hilsenroth et al., 2000; 
Hay et al., 2003). 
In measuring patients’ social and work adjustment we used the Social Adjustment 
Scale-Self Report (SAS-SR; Weissman & Bothwell, 1976). In contrast to SOFAS, SAS-
SR is a subjective self-rated scale. The lowest score of 1 indicates optimal functioning 
and 5 the worst functioning for each of the 54 questions. The internal consistency of our 
translation of the SAS-SR was moderate to good, with Cronbach’s Alpha for the 
subscale work outside home 0.73, work at home 0.69, work as a student 0.82, social and 
leisure 0.69, extended family 0.53, marital 0.63, parental 0.67, and family unit 0.62. The 
economic subscale contains only one question. We calculated mean values for all 
subscales related to the patient’s work and family relationships, and the overall score 
for every patient. 
Social support given by the family, friends, and significant others was measured by the 
Perceived Social Support Scale – Revised (PSSS-R; Blumenthal et al., 1987) the 
shortened version with a 1–5 scale for each of 12 questions. Although both SAS-SR and 
PSSS-R in part measure family relations, SAS-SR items focus on social adjustment and 
functioning, PSSS-R on perceptions of relations with family and significant others. The 
Beck Anxiety Inventory (BAI; Beck et al 1988) includes mainly somatic symptoms; it 
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focuses the patient’s attention to those which weaken the patient’s functioning. The 
Beck Hopelessness Scale (HS; Beck et al 1974) is also a self-report scale providing data 
concerning patients’ hopelessness about their future. The Eysenck Personality Inventory 
(EPI; Eysenck & Eysenck, 1964) is a self-report scale of personality traits, i.e., 
neuroticism and intro- and extraversion. The number of days from baseline spent ill in 
bed (over 50% of the time spent awake) due to depression were recorded both in 6- and 
in 18-month follow-up interviews. 
6.3.5 Treatment received 
Psychosocial treatment was analysed: its type, length, and the number of visits both to 
psychiatrist and medical personnel. Patients’ antidepressant treatment was carefully 
recorded at both follow-up points. Its length, dosage, any switch to another medicine, 
additional medication (somatic medicines, neuroleptics, anxiolytics, hypnotics), 
possible augmentation medications and use of electroconvulsive therapy (ECT) were 
recorded.
6.3.6 Work status 
Current work status and length of sick-leave (granted by a physician) were recorded at 
every interview point. These were based on patients’ self reports and the medical 
records in use at interview. 
6.3.7 Follow-up 
6.3.7.1 Follow-up cohorts 
At baseline, all VDS subjects (269) with current MDD were included Study I. At the 6-
month follow-up point, 40 subjects were missing (n=229). Some of these were 
participating in the study again at the 18-month follow-up (n=207). Only 13% (35/269) 
dropped out of both follow-up interviews. Of the 269 subjects at baseline, 13 (5%) 
patients’ diagnoses switched to bipolar disorder during the 18-month follow-up. They 
were censored from the analyses, and 8 patients died during follow-up. The median 
time points to follow-up interviews were 6.5 and 18.8 months. Of the remaining 198 
patients prospectively followed up, those were analysed in Study III who had at every 
interview data from SOFAS (191) and SAS-SR (N=192) and the number of days ill in 
bed (N=193). This cohort of 193 patients included those who also had all the data from 
SOFAS and SAS-SR mentioned above. For Study IV, of the 198 patients prospectively 
followed up, we excluded those already pensioned at baseline. The remaining 186 
patients were classified into two groups as follows; 1) those who at 18 months were still 
in the labour force (n=99) or were unemployed (n=29), on sick-leave (n=14), were 
students (n=13) or others (n=10), and 2) those who were granted a long-term work 
disability pension due to MDD during follow-up (n=21). The majority of subjects in the 
cohort were women (134, 72%), and the overall mean age was 42.1 (SD 10.8). 
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6.3.7.2 Follow-up process 
After baseline, patients were investigated at 6 and 18 months from baseline with the life 
chart methodology of depression severity and the scales mentioned above. The life-
chart methodology was based on DSM-IV criteria and definitions. Time after the first 
baseline interview was examined, divided into three periods: 1) state of full remission, 
2) state of partial remission, or 3) state of MDE. Full or partial remission was defined as 
at least two consecutive months during which the patient did not fulfil the MDE criteria 
(full=0, partial=1-4 of the 9 symptoms) according to the DSM-IV. Relapse was defined 
as return of symptoms fulfiling the MDE criteria for more than 2 weeks, but less than 2 
months, after a period of more than 2 weeks, but less than 2 months spent below the 
MDE threshold. Recurrence was defined as a return of symptoms fulfiling the criteria of 
MDE after at least 2 consecutive months of partial or full remission. 
We employed a Likert scale to investigate patients’ self-reported treatment adherence 
with the following response items: been on antidepressants 1) regularly; treatment 
compliance adequate with respect to treatment goals, 2) somewhat irregularly; it is 
unclear whether this would affect treatment goals, 3) very irregularly; the treatment did 
not proceed according to plan, and 4) not at all; the provided treatment could not be 
implemented. Hospital treatment periods during follow-up were ascertained in the 
medical records. 
6.3.8 Statistical analyses 
The record-based study employed logistic regression models, using stepwise backward 
elimination with the likelihood ratio test as the criterion for removal to control for age, 
gender, and other possible confounding factors. The chi-square test was used with Yates 
correction in all four studies. Variables were dichotomized if needed. The Kruskal-
Wallis test and one-way analysis of variance (ANOVA) were also used. 
In Study II, the Mann-Whitney and Kruskal-Wallis tests were employed in comparisons 
of continuous variables not normally distributed, and the two-sample t-test was used for 
variables normally distributed. Because SOFAS and SAS-SR scales were normally 
distributed, we employed multivariate linear regression models. The multivariate 
models included linear regression models, with SOFAS score as the dependent variable. 
In analysing SAS-SR subscales and overall scores a linear regression model was 
employed, with the independent factors of gender, age, total duration of depression 
including prodromal time and duration of depression prior to baseline Ham-D, phobic 
disorders including agoraphobia, specific and social phobia, alcoholism, and any 
personality disorder. Factors associated with sick-leave were analysed by logistic 
regression models including gender, age, Ham-D, and number of previous episodes 
(classified as none, one, and two or more) as the independent variables. 
In Study III, the bivariate correlations of SOFAS and SAS-SR were calculated by 
Pearson Correlation. Univariate statistical analyses of SOFAS and SAS-SR employed 
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ANOVA. Overall scores of SAS-SR and SOFAS values were analysed by a linear 
regression model, with the independent factors at 6 months being gender, age, marital 
status, Ham-D, and phobic disorders including agoraphobia, specific and social phobia, 
alcoholism, any personality disorder, any somatic disease for which patients were 
receiving medical treatment, and BAI and PSSS-R. In analysing factors associated with 
disability at 18 months, independent variables were those mentioned, and in addition 
time spent in full remission, in partial remission, or fulfiling the criteria of MDE, and in 
addition having a relapse or recurrence the during follow-up time or not. Dependent 
variables too skewed for linear regression were dichotomized by the median of the 
variable.
In Study IV, Fisher’s exact test was used instead of the chi-square analysis in some 
analyses, where some cell(s) contained less than five cases. ANOVA served for 
comparisons of continuous variables. In all analyses, item 7 in the Ham-D and item 15 
in the BDI, capacity for work, was omitted in order to avoid circularity. Three different 
logistic regression models were employed to investigate 1) baseline factors predicting 
pension, 2) effect of duration of depression, and 3) independent prediction by sick-leave 
at baseline of received a disability pension. We first adjusted for gender, age, marital 
status, severity and number of previous episodes of depression, alcoholism, personality 
disorders, BAI, PSSS-R, HS, SSI, SAS-SR, and SOFAS scores at baseline, and duration 
of depression, and then omitted non-significant factors. 
The analysis program used was SPSS, versions 9.01 and 13.0 (SPSS Inc. 1989-2004). 
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7. RESULTS 
7.1 Treatment received for depression in psychiatric care (Study I) 
7.1.1 Clinical and sociodemographic characteristics of the cohort
The vast majority of those receiving a clinical diagnosis of MDE were females, 513 of 
803 (63.9%). One-fifth (20%) of both genders made inpatient visits, with a mean of 1.8 
inpatient treatment periods (median=1, range 1-20) during the overall treatment period 
investigated. The median length of a hospital stay was 14 days. During the whole 
treatment period, the depressed patients averaged only a few visits to psychiatrists 
(median=2; range, 1-52), but more to other health professionals including psychiatric 
nurses, social workers, and psychologists (median=7; range, 1-148). Half the subjects 
(52%) were married or cohabiting. One-third (32%) were employed at the beginning of 
the treatment period; and more (34%) at the end of the treatment or follow-up (at the 
end of 1997). Detailed data on clinical and sociodemographic characteristics are 
presented in Table 2. Genders differed significantly only for alcohol misuse, men 
showing this twice as often as women. 
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Table 2. Sociodemographic characteristics of the 803 psychiatric patients in the 
Peijas Medical Care District of Vantaa, Finland. 
a = Males vs. females Chi2 = 33.4, df = 1, p<0.0001 
 Males Females Total
(n=290) (n=513) (n=803) 
Mean age ?SD(y) 43 ? 9.3 43 ? 10.2 43 ? 9.9 
Marital status (%) 
 Married 42 41 41 
 Cohabiting 12 11 11 
 Divorced 29 31 31 
 Widowed 1 4 3 
 Unmarried 16 13 14 
Occupational status (%) 
 Entrepreneur 10 3 5 
 White-collar worker 26 36 33 
 Blue-collar worker 57 50 52 
 Pensioner 3 4 4 
 Student 4 4 4 
 Other 0 3 2 
Work status at the beginning of the treatment (%)  
 Unemployed 27 20 22 
 On sick-leave 20 20 20 
 Pensioned, psychiatric reason 14 14 14 
 Pensioned, somatic reason 6 3 4 
 Employed 30 33 32 
 Studying 3 4 4 
 Other 0 4 3 
 Unknown 0 1 1 
Work status at end of treatment or follow-up (%)  
 Unemployed 22 13 16 
 On sick-leave 10 8 8 
 Pensioned, psychiatric reason 30 28 29 
 Pensioned, somatic reason 7 3 5 
 Employed 27 37 34 
 Studying 2 5 4 
 Other 0 3 2 
 Unknown 0 2 1 
 Deceased 2 0 1 
Severity of depression (%) 
 Mild 7 10 9 
 Moderate 35 37 36 
 Severe 29 29 29 
 Severe with psychotic features 11 9 10 
 Undefined 18 15 16 
Use of alcohol (%)a
 No alcohol misuse 61 80 73 
 Alcohol misuse 39 20 27 
Previous psychiatric care (%) 
 No 52 49 50 
 Yes 48 51 50 
Quartiles of duration of current treatment period (week)  
 25 16 23 21 
 50 60 65 63 
 75 119 121 120 
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7.1.2 Antidepressant treatment 
Of the 803 patients, 675 (84.1%) underwent at least one antidepressant trial. 
Antidepressant treatment received by degree of depression severity was the following: 
mild, 49 of 72 (68.1%); moderate, 251 of 292 (86.0%); severe, 211 of 232 (90.9%); 
psychotic, 70 of 80 (87.5%); not specified, 94 of 127 (74.0%). A minority (11.3%) of 
these took clearly subtherapeutically low doses. Selective serotonin reuptake inhibitors 
(SSRIs) and other newer antidepressants were used in adequate doses in nearly all (527) 
cases: 514 (97.5%), whereas of 148 those receiving tricyclic antidepressants (TCAs) 
took adequate doses only 70 (47.3%) (Chi2=245.7, p<0.0001). 
The antidepressants used are shown in Table 3. The newest, mirtazapine and 
venlafaxine, had been in use for only a short period. In a logistic regression model with 
stepwise backward elimination, including gender, living alone or together, occupation, 
alcohol misuse, use of anxiolytics and hypnotics, and degree of severity of depression 
as covariates, use of TCAs was significantly associated with older age (odds ratio per 
year of age=1.06, Wald Chi2=19.92, df=1, p<0.0001, 95% confidence interval 
[CI]=1.03 to 1.08), previous psychiatric care (odds ratio=1.58, Wald Chi2=4.52, df=1, 
p=0.03, 95% CI=1.04 to 2.42), and use of neuroleptics (odds ratio=2.57, Wald 
Chi2=17.70, df=1, p<0.0001, 95% CI=1.65 to 3.98). 
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Table 3. Characteristics of antidepressant treatment periods by type of antidepressant. 
Mean dosea Dose range Median 
 N (%) (mg) (mg) durationb,c (wk) 
Tricyclics
 amitriptyline 70 (10.4) 93 (25.– 250) 96 
 clomipramine 33 (4.9) 120 (10.– 250) 51 
 doxepin 30 (4.4) 85 (25.– 250) 67 
 imipramine 2 (0.3) 138 (125.– 150) 5 
 nortriptyline 1 (0.1) 100 (100) 163 
 trimipramine 12 (1.8) 92 (50.– 150) 70 
SSRIs
 citalopram 138 (20.4) 28 (10.– 60) 63 
 fluoxetine 184 (27.3) 26 (8.– 60) 34 
 fluvoxamine 26 (3.9) 102 (50.– 300) 35 
 paroxetine 16 (2.4) 23 (20.– 40) 28 
 sertraline 16 (2.4) 84 (50.– 200) 44 
Tetracyclics
 maprotilin 6 (0.9) 81 (38.– 150) 89 
 mianserin 54 (8.0) 54 (10.– 90) 29 
 trazodone 12 (1.8) 208 (100.– 300) 74 
NaSSA
 mirtazapine 6 (0.9) 30 (15.– 45) 21 
SNRI
 venlafaxine 1 (0.1) 75 (75) - 
RIMA
 moclobemide 68 (10.1) 417 (150.– 600) 32 
Total  675 (100.0)   44 
a = Means of highest daily doses used during treatment, b = Exact duration of treatment 
unknown in 59 cases, c = Duration of use of tricyclics vs. SSRIs, vs. tetracyclics and vs. 
others significantly longer (in Kruskal-Wallis test Chi2=11.68, df=3, p=0.009) 
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7.1.2.1 Antidepressant switching strategies 
Switching strategies of antidepressants were quite conservative: Among the 675 
patients, the first antidepressant had been switched to another compound for only one-
fourth of those receiving any antidepressant, 174 (25.8%), and to a third compound for 
only 36 (5.3%) patients (Figure 4). Only two patients had undergone up to five 
antidepressant trials. During the whole treatment period, only TCAs were prescribed for 
113 (14.1%), SSRIs only by 307 (38.2%), and other antidepressants only by 106 
(13.2%). At least two different types of antidepressants were prescribed for 149 
(18.6%). The median duration of the first antidepressant trial was about 10 months 
(median 44 weeks, range 0.4-524 weeks). Of the 675 patients 47 (7%) were on 
antidepressant combinations. No significant differences appeared between genders in 
terms of receiving only one or two antidepressants. No other augmentation medications 
were prescribed. 
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50Figure 4. The three first antidepressants used, and changed. TCAs are in light green, SSRIs in blue, others in brown and no
antidepressant at all in red. Width of borders of the boxes and of the arrows represent the number of patients using
antidepressants or having their antidepressants changed. Numbers besides the arrows of the same colour represent number of
antidepressant changed. 
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7.1.2.2 Antidepressants received by pensioned patients 
During the treatment period, of the 655 not before pensioned, 125 (19%) were granted a 
disability pension due to the psychiatric reasons. Two-thirds (67%) of the pensioned 
patients had received only a single antidepressant trial or none at all, but 82% of the 
other patients. The first antidepressant trial was equally long for both groups (44 vs. 45 
weeks, NS). Those patients granted a disability pension for major depression received 
TCAs more often than did others (31% vs. 11%). Being granted a disability pension 
was significantly associated with use of TCAs (Chi2=29,5, df=1, p<0.0001). This 
finding remained significant after adjusting for possible confounding factors (age, 
gender, living with a partner, occupation, work status at the beginning of treatment, 
severity of depression, alcohol misuse, and use of anxiolytics, hypnotics, and 
neuroleptics) in the logistic regression model with stepwise backward elimination (odds 
ratio=2.17, Wald Chi2=7.39, df=1, p=0.007, 95% CI=2.17 [1.24, 3.78]). 
7.1.3 Patient drop-outs and refusal of treatment 
One-fifth of the cohort (22%) were drop-outs from outpatient visits. In the logistic 
regression model, dropping out was significantly predicted by younger age (odds ratio 
per year of age=1.03, Wald Chi2=7.72, df=1, p=0.006, 95% CI=1.03 [1.01, 1.05]), 
being employed at the beginning of treatment (odds ratio=1.60, Wald Chi2=4.81, df=1, 
p=0.03, 95% CI=1.60 [1.05, 2.44]), and milder severity of depression (odds ratio=2.35, 
Wald Chi2=17.83, df=1, p<0.0001, 95% CI=2.35 [1.58, 3.49]). The most common 
explanation for not receiving antidepressants was refusal. Subjective reasons for this 
were impossible to ascertain. Markedly more common refusals occurred among those 
with mild rather than more severe degrees of depression (8.0 % vs. 3.5 %, Chi2=5.182,
df=1, p=0.03), and were also associated with younger age and being employed after 
treatment. 
7.1.4 Changes in work status and treatment of pensioned patients 
Only a minimal change occurred in the proportion of employed patients at the end of 
the treatment period compared with at the beginning (Table 2). Pensioned patients (125) 
were significantly older than those not receiving a pension (mean ages 48.5 vs. 39.7 
years, one-way ANOVA p>0.0001). Patients granted a work disability pension suffered 
more often from severe or psychotic depression than did others (58% vs. 42%, 
p=0.0001). Their psychosocial and medication treatment also was more intensive than 
the others’: more visits to professionals than the others (mean 15.1 vs. 9.4, median 11 
vs. 7, one-way ANOVA p=0.0003), and significantly more concomitant medications; 
including anxiolytics 53% vs. 36% (p=0.001), hypnotics 43% vs. 33% (p=0.03) and 
neuroleptics 42% vs. 29% (p=0.007). 
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7.2 Functional and work disability in depression (Study II) 
7.2.1 Level of social and occupational functioning 
Patients at the baseline of VDS suffered from functional disability currently ranging 
from mild to severe (SOFAS mean ± SD=51.8 ± 10.85, median=55.0, range 20 - 80). 
The most significant predictor of low SOFAS score was high severity of depression. 
Differences between in- or outpatients, or those at work or on sick-leave, were also very 
significant. Older age and any personality disorder, especially cluster A or C, were 
associated with lower SOFAS scores (Table 4). In a multivariate linear regression 
model adjustment for gender and age and with SOFAS as the dependent variable, 
severity of depression (Ham-D score) was the most significant factor associated with 
disability (p<0.001), and number of previous episodes of depression also predicted 
disability (p=0.013). 
7.2.2 Social adjustment 
Patients showed considerable variation in their social adjustment across different areas 
of social life. Both the mean and median overall SAS-SR scores were 2.47, range 1.33 
to 3.69. In contrast to the findings related to SOFAS, Axis I and II comorbidity had a 
significant independent impact on patients’ social adjustment. In the linear regression 
models, after adjusting for gender and age, we found that severity (Ham-D) (p<0.001 in 
overall score) and total duration of depression (p=0.003 for overall score), and phobic 
disorders (p=0.001 in overall score) were the most significant factors predicting poor 
social adjustment. Personality disorders had the most significant effect for the social 
and leisure subscale (p<0.001). Alcoholism was the dominant factor for the economic 
subscale (p=0.002), and phobic disorders were significant in the family-related 
subscales (p=0.005 in the extended family and p=0.008 in the family unit subscale). 
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Table 4. Differences between SOFAS and SAS-SR overall scores of the Vantaa 
Depression Study cohort according to sociodemographic and clinical characteristics. 
SOFAS SAS-SR 
N Mean SD M-Wza p N Mean SD M-Wza p
Gender  
 Male 71 52.9 11.2   71 2.53 0.46 
 Female 196 51.4 10.7   197 2.45 0.45 
Age group 
 20 – 39 132 53.5 10.9   131 2.48 0.44 
 40 – 59 135 50.2 10.6 -2.57 0.01 137 2.46 0.47 
In- or outpatient  
 Inpatients 46 41.7 13.1   46 2.53 0.50 
 Outpatients 221 53.9 9.0 -6.22 <0.0001 222 2.46 0.45 
Work status  
 On sick-leave 67 46.5 10.7   68 2.50 0.46 
 Working 89 57.9 7.4 -6.89 <0.0001 89 2.44 0.44 
Anxiety Disorder  
 None 116 52.7 11.4   116 2.39 0.46 
 Any 151 51.1 10.4   152 2.54 0.45 -2.49 0.013 
Phobic Disorder  
 None 158 52.5 10.8   158 2.39 0.45 
 Any 109 50.8 10.9   110 2.60 0.44 -3.70 0.0002 
Personality Disorder  
 None 149 53.5 10.7   150 2.39 0.44 
 Any 118 49.8 10.8 -2.73 0.006 118 2.58 0.45 -3.34 0.001 
Cluster A 
 No 216 52.5 10.9   217 2.46 0.47 
 Yes 51 49.0 10.1 -2.33 0.02 51 2.54 0.39 
Cluster B 
 No 228 52.1 11.0   229 2.44 0.46 
 Yes 39 50.1 9.6   39 2.64 0.41 -2.62 0.009 
Cluster C 
 No 182 53.0 10.5   183 2.41 0.44 
 Yes 85 49.4 11.3 -2.36 0.018 85 2.59 0.46 -2.67 0.008 
Alcohol abuse or dependence  
 No 201 52.4 10.1   203 2.42 0.46 
 Yes 66 50.0 12.8   65 2.62 0.41 -2.95 0.003 
N Mean SD K-W Chi2b p N Mean SD K-W Chi2b p
a M-W z = Mann-Whitney test, z, b K-W Chi2 = Kruskal-Wallis test, Chi2
Severity of depression  
 Mild 16 59.4 7.3   17 2.18 0.41 
 Moderate 134 57.7 7.3   134 2.41 0.42 
 Severe or  
 psychotic 117 44.0 9.6 122.31 <0.0001 117 2.59 0.47 14.06 0.001 
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7.2.3 Effect on sick-leave 
The work status of the cohort at baseline is shown in Table 5. 
Table 5. Work status of the Vantaa Depression Study cohort at baseline. 
Work status Male Female Total 
N % N % N % 
Employed 33 45.8 56 28.4 89 33.1 
Sick-leave 11 15.3 57 28.9 68 25.3 
Unemployed 20 27.8 37 18.8 57 21.2 
Student 3 4.2 21 10.7 24 8.9 
Pensioned for psychiatric reason 3 4.2 7 3.6 10 3.7 
Pensioned for somatic reason 0 0.0 3 1.5 3 1.1 
Other 1 1.4 12 6.1 13 4.8 
Unknown 1 1.4 5 2.0 6 2.2 
Total 72 100.0 197 100.0 269 100.0 
Two-fifths of 157, 68 (43%) of the employed patients were on sick-leave, with a 
significant gender difference: of 44 males, 11 ( 25.0%), vs. 57 (50.4%) of 113 females 
(Chi2=7.35, df=1, p=0.007). Furthermore, a strong non-linear relationship emerged 
between age and work status. Significantly more of the employed 20 to 49-year-old 
patients were at work compared to those 50 to 59 years old: of 125, 80 (64.0%), vs. 9 
(28.1%) of 32, respectively, (Chi2=11.93, df=1, p=0.001). 
Employed patients suffering from mild to moderate depression were more often at work 
than were those with severe to psychotic depression: of 92, 67 (72.8%) vs. 22 (33.8%) 
of 65(Chi2=22.01, df=1, p<0.0001). Patients at work had significantly lower Ham-D 
scores than did those on sick-leave in the paired t-test (17.0 vs.18.9, paired t=2.26, 
df=155, p=0.025). Patients on sick-leave had significantly more prior episodes of 
depression than did those at work (mean 2.00, range 0-20, vs. 1.06, range 0-5, Mann-
Whitney p=0.027). In the older age group (40-59 years), patients with a somatic disease 
receiving medical treatment were more often on sick-leave than were those without: of 
46, 24 (52.2%) vs. 13 (29.5%) of 44, (Chi2=3.87, df=1, p=0.049). Neither substance 
abuse of the 35 on sick-leave, affecting 12, Chi2=1.06, df=1, p=0.303) nor personality 
disorders of the 72 on sick-leave, 34 (Chi2=0.56, df=1, p=0.454) had a significant 
impact on likelihood of sick-leave. Independent predictors of sick-leave in the final 
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logistic regression model were female gender, age, severity of depression, and number 
of episodes of depression (Table 6). 
Table 6. Results of the multivariate logistic regression model of the Vantaa Depression 
Study patients at work or on sick-leave. 
Variable Logistic    95% confidence 
 coefficient S.E P-value Odds ratio interval 
Female gender 1.3738 0.4456 0.0020 3.9502 1.65 - 9.46 
Age 0.0520 0.0192 0.0068 1.0534 1.01 - 1.09 
Ham-D 0.0765 0.0346 0.0269 1.0796 1.01 -1.16 
Number of episodes  0.4587 0.2195 0.0366 1.5821 1.03 - 2.43 
of depression a
a = Classified as none, one, or two or more previous episodes, Ham-D = Hamilton Rating 
Scale for Depression 
7.3 Functional disability and social adjustment in MDD (Study III) 
7.3.1 Sociodemographic and clinical characteristics of the cohort 
During the follow-up from baseline through 6 to 18 months, patients’ symptoms of 
depression dissolved, global disability was alleviated, and social adjustment was 
strengthened. Both social and occupational functioning (lower worst) and social 
adjustment values (higher worst) correlated well at 6 and 18 months (Pearson 
Correlation -0.605 and -0.547, respectively, both significant at the 0.01 level). 
Patients included in the follow-up were significantly (nearly 5 years) older than those 
not in the follow-up cohort (age 36.1 years, ANOVA F=11.24, p=0.001). Groups did 
not differ from each other in terms of the other characteristics in Table 7. During 
follow-up, symptoms of depression, anxiety, and hopelessness diminished, and patients 
perceived their social support as a little better. Their disability, assessed by all tools 
used, was alleviated. Patients’ clinical data at baseline and at 6 and 18 months are 
shown in Table 8. 
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Table 7. Sociodemographic and clinical characteristics of MDD patients at baseline in 
the follow-up study. 
Variable Baseline 
 N=193 
Sociodemographic characteristics 
 Age, years (S.D.) 41.0 (11.1) 
 Females (%) 139 (72.0) 
 Married or cohabiting (%) 104 (53.9) 
 Secondary school level of education (%) 68 (35.2) 
 Below secondary school level (%) 125 (64.8) 
Clinical characteristics 
 Outpatients (%) 163 (84.5) 
 No previous episodes of depression (%) 65 (33.7) 
 One or more episodes of depression (%) 128 (66.3) 
 Achieved full remission during follow-up time (%) 117 (60.6) 
 Did not achieve full remission during follow-up (%) 76 (39.4) 
Table 8. Baseline, 6-, and 18-month clinical data for MDD patients (N=193) in the 
follow-up study. 
Variable Baseline 6 months 18 months 
Mean SD Mean SD Mean SD 
Ham-D a 17.1 5.3 8.2 6.7 7.1 6.4 
BDI b 25.8 7.9 11.9 9.0 10.4 9.5 
BAI 21.5 10.6 13.2 9.8 11.6 10.3
PSSS-R 39.1 12.9 41.9 12.9 42.6 13.5 
HS 10.1 4.7 7.5 5.2 6.4 4.8 
SOFAS c 52.4 10.4 67.2 14.4 72.5 14.4 
SAS-SR overall d 2.4 0.4 2.1 0.5 2.0 0.4 
Number of days spent ill 
 in bed from baseline   12.8 28.0 21.8 53.2 
a =Without item 7, ability to work, b =Without item 15, ability to work, c = One value 
missing at baseline and at 18 months, d = One value missing at 18 months, Ham-D, 
Hamilton Rating Scale for Depression, BDI, Beck Depression Inventory, BAI, Beck 
Anxiety Inventory, PSSS-R, Perceived Social Support Scale – Revised, HS, Beck 
Hopelessness Scale, SOFAS, Social and Occupational Functioning Assessment Scale for 
DSM-IV, SAS-SR, Social Adjustment Scale-Self Report, overall score 
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7.3.2 SOFAS and SAS-SR univariate analyses 
The most important factors predicting social and occupational disability and poor social 
adjustment at the18-month follow-up in ANOVA analyses were recurrent depression at 
baseline (two or more lifetime episodes) (in SOFAS p=0.004 and SAS-SR p=0.005) and 
not achieving full remission during follow-up (in SOFAS p<0.001 and SAS-SR 
p<0.001). Having either any, or specifically, a cluster C (obsessive-compulsive, 
dependent, avoidant, and passive-aggressive) personality disorder was an important 
factor predicting social and occupational disability (any or none p=0.006 and cluster C 
p=0.006) and poor social adjustment any or none p=0.002 and cluster C p=0.017). 
During the course of depression, the social adjustment of women (p=0.015) improved 
significantly more than did men’s. Similar better improvement was also as a trend in 
social and occupational functioning for women (p=0.056). The older age group was 
slightly more disabled than was the younger. 
7.3.3 Predictors of disability from baseline to 6 months 
SOFAS values and overall scores of SAS-SR at 6 months were analysed by a linear 
regression model, with these independent factors at baseline: gender, age, marital status, 
Ham-D, and phobic disorders including agoraphobia, specific and social phobia, 
alcoholism, any personality disorder, any somatic disease for which patients were 
receiving medical treatment, and BAI and PSSS-R. The strongest predictive factors for 
SOFAS were BAI (p=0.001), PSSS-R (p=0.002), and number of previous episodes of 
depression (p=0.008), and for SAS-SR, overall scores were BAI (p<0.001) and PSSS-R 
values (p=0.001) and number of previous episodes of depression (p=0.001): classified 
as none or as one or more previous episodes. 
7.3.4 Predictors of disability from 6 to 18 months 
SOFAS values and overall scores of SAS-SR at 18 months were analysed by a linear 
regression model, with the independent factors at 6 months mentioned above. The most 
significant factors predicting SOFAS at 18 months were degree of depression (Ham-D; 
p<0.001), perceived social support (p=0.002), and having any previous episode of 
depression (p=0.040). Poor social adjustment was mostly associated with lack of 
perceived social support (p<0.001) and higher scores of neuroticism (p<0.001). Degree 
of depression at 6 months was significant to a lesser degree (p=0.036). 
7.3.5 Predictors of disability at 18 months 
Factors predicting disability and problems in social adjustment at 18 months were 
analysed by linear regression models with other factors as described in statistical 
methods. Current degree of depression (Ham-D; p<0.001), higher BAI score (p=0.039), 
worse perceived social support (p=0.005), shorter time in full remission during 18 
months (p=0.004), and relapse or recurrence during 18 months (p=0.010) were very 
Lopullinen.pdf   57 14.9.2006   10:36:28
58
significant factors predicting poor social and occupational functioning. Poor social 
adjustment was significantly associated with the degree of depression (p=0.025), higher 
BAI score (p<0.001), worse perceived social support (p<0.001), relapse or recurrence 
during 18 months (p=0.001), and higher neuroticism score (p<0.001). 
7.3.6 Predictors of days spent ill in bed 
Nearly half (90 of 193, 46.6%) of the patients spent at least one day ill in bed because 
of depression during the whole 18-month follow-up time (range from 2 to 500, mean 
values in Table 8). Excluding those with no bed days, mean ± SD for number of days 
spent ill in bed was 46.7 ± 70.2 and median 20.0 days during the whole follow-up time. 
In the logistic regression model, we found that the most significant factors predicting 
days spent ill in bed (dichotomized to no or any days spent ill in bed) were severity of 
depression (Ham-D) at baseline (p=0.001), time spent in MDE during 18 months 
(p=0.018), and having any phobic disorder (p=0.046). 
7.4 Long-term work disability in MDD (Study IV) 
7.4.1 Sociodemographic and clinical differences 
In the 18-month follow-up 186 patients participating were not pensioned at baseline. Of 
these 21 (11.3%) were granted a disability pension during the 18-month follow-up. The 
patients who had received a pension were significantly older, less often had vocational 
education and were more often on sick leave than those not pensioned, but did not differ 
with regard to any other sociodemographic or clinical factors (Table 9.). However, at 
the 6-month follow-up, these groups had differed in nearly all variables, with these 
differences diminishing over the following year (Table 10). Two-thirds (14 of 21, 67%) 
of pensioned patients vs. one-fourth (42 of 161, 25%) of those not pensioned (df=1, 
Chi2=13.6, P<0.001) were on sick leave at baseline. The mean time spent in major 
depressive episodes (MDEs) was 10.6 months for pensioned patients and 4.1 months in 
non-pensioned patients (ANOVA F=34.4, P<0.001, medians 13.7 and 2.5 months, 
respectively). One-third (7 of 21) of pensioned patients vs. only 3% of the others (5 of 
165, df=1, Chi2=23.5, P<0.001) did not reach even partial remission during follow-up. 
Social phobia was the only Axis I or II comorbid disorder to be more common among 
pensioned patients (8 of 21, 38% vs. 25 of 165, 15%, df=1, Chi2=5.2, P=0.022). 
In a logistic regression analysis adjusted for gender, age, and severity of depression, 
greater age, hopelessness, disability, and no vocational education predicted disability 
pension (Table 11). The time spent in MDE during the 18 months was very significant 
when included in the model, with hopelessness remaining only a trend (Table 12). 
Finally, we analysed the same model, including the variable “being on sick leave” at 
baseline, and omitting SOFAS to avoid circularity. In this model, male gender became 
significant and hopelessness disappeared. After all adjustments, the risk for being 
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granted a disability pension during the next 18 months was markedly elevated (OR 6.1) 
among patients on sick leave at baseline (Table 13). 
Table 9. Sociodemographic and clinical data at baseline for patients pensioned or not 
pensioned at the 18-month follow-up. 
 Not pensioned Pensioned Total
 (n=165) (n=21) (n=186)
Female, n (%) 120. 72.7 14. 66.7 134. 72.0 
Age at 18-month, mean (SD) a 40.8 10.5 52.4 7.6 42.1 10.8 
Married or cohabiting, n (%) 87. 52.7 13. 61.9 100. 53.8 
No vocational education, n (%) b 61. 37.0 13. 61.9 112. 60.2 
Inpatients, n (%) 22. 13.3 4. 19.0 160. 86.0 
On sick leave, n (%) c 40. 24.2 14. 66.7 54. 29.0 
Severity of depression 
 Mild, n (%) 9 5.5 2 9.5 11 5.9 
 Moderate, n (%) 92 55.8 7 33.3 99 53.2 
 Severe without psychotic sympt. n (%) 61 37.0 12 57.1 73 39.2 
 Severe with psychotic sympt. n (%) 3 1.8 0 0.0 3 1.6 
Recurrence of depression 
 First episode, n (%) 61 37.0 4 19.0 65 34.9 
 Recurrent depression, n (%) 104 63.0 17 81.0 121 65.1 
MDD without comorbidity, n (%) 39 23.6 3 14.3 42 22.6 
Axis I comorbidity 
 Dysthymia, n (%) 15 9.1 4 19.0 19 10.2 
 Any anxiety disorder, n (%) 88 53.3 13 61.9 101 54.3 
 Any alcohol use disorder, n (%) 35 21.2 3 14.3 38 20.4 
a = ANOVA F=24.1, p<0.001, b = Chi2=3.9, p=0.050, c = Chi2=14.3, p<0.001 
Axis II comorbidity 
 Any personality disorder, n (%) 68 41.2 12 57.1 80 43.0 
 Cluster A, n (%) 31 18.8 5 23.8 36 19.4 
 Cluster B, n (%) 23 13.9 4 19.0 27 14.5 
 Cluster C, n (%) 49 29.7 9 42.9 58 31.2 
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Table 10. Mean and standard deviation (SD) values of univariate analyses of patients 
pensioned or not pensioned at the 18-month follow-up. 
 Not pensioned Pensioned F P
BDI at baseline, mean (SD) 25.5 7.7 27.8 8.1 1.7 0.188 
BDI at 6 months, mean (SD) a  10.7 8.7 19.4 8.4 18.9 <0.001 
BDI at 18 months, mean (SD) b 9.9 9.4 15.2 9.8 5.9 0.016 
Ham-D at baseline, mean (SD) 16.9 5.3 19.6 4.3 4.9 0.028 
Ham-D at 6 months, mean (SD) a 7.4 6.5 13.3 6.5 15.3 <0.001 
Ham-D at 18 months, mean (SD) 6.7 6.2 10.4 6.9 6.4 0.012 
SOFAS at baseline, mean (SD) b 53.6 10.2 47.2 6.7 7.7 0.006 
SOFAS at 6 months, mean (SD) a 69.4 13.8 53.9 8.0 25.1 <0.001 
SOFAS at 18 months, mean (SD) b 73.9 13.8 65.6 14.8 6.5 0.012 
SAS-SR overall at baseline, mean (SD) 2.4 0.4 2.6 0.3 3.5 0.062 
SAS-SR overall at 6 months, mean (SD) c 2.0 0.5 2.4 0.3 13.7 <0.001 
SAS-SR overall at 18 months, mean (SD) d 2.0 0.5 2.1 0.4 1.2 0.271 
BAI at baseline, mean (SD)  21.1 10.8 27.6 8.2 7.0 0.009 
BAI at 6 months, mean (SD) a 11.9 9.3 22.0 7.4 22.8 <0.001 
BAI at 18 months, mean (SD) 10.9 10.0 15.4 10.5 3.7 0.057 
PSSS-R at baseline, mean (SD) 39.6 12.7 34.3 12.6 3.2 0.075 
PSSS-R at 6 months, mean (SD) a 42.9 12.8 35.5 12.4 6.3 0.013 
PSSS-R at 18 months, mean (SD) 43.5 13.0 37.6 16.6 3.6 0.058 
HS at baseline, mean (SD) 9.9 4.6 12.8 4.1 7.7 0.006 
HS at 6 months, mean (SD) a 6.8 5.0 11.7 4.2 18.2 <0.001 
HS at 18 months, mean (SD) d 6.1 4.8 8.6 5.4 5.1 0.025 
SSI at baseline, mean (SD) b 5.5 7.4 10.6 9.6 8.2 0.005 
SSI at 6 months, mean (SD) e,f 1.6 4.1 3.6 7.5 2.6 0.107 
SSI at 18 months, mean (SD) a, f 1.2 3.8 3.0 6.7 3.0 0.084 
a = Data on 5 patients missing in not-pensioned group, b = Data on one patient missing in 
not-pensioned group, c = Data on 4 patients missing in not-pensioned group, d = Data on 2 
patients missing in not-pensioned group, e = Data on 56 patients missing in not-pensioned 
group, f = Data on 4 patients missing in pensioned group 
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Table 11. Logistic regression model of significant clinical baseline variables. The 
dependent variable is either being pensioned or not pensioned at the 18-month follow-
up.
Variable B S.E. Wald P OR 95% CI for B 
Age 0.144 0.041 12.327 0.0004 1.155 1.066; 1.251 
HS 0.204 0.073 7.683 0.0056 1.226 1.061; 1.415 
SOFAS -0.075 0.030 6.200 0.0128 0.928 0.875; 0.984 
No vocational
education 1.241 0.580 4.576 0.0324 3.461 1.110; 10.792 
HS = Beck Hopelessness Scale , SOFAS = Social and Occupational Functioning 
Assessment Scale. 
Table 12. Logistic regression model of significant clinical baseline variables and time 
spent in MDE during the 18-month follow-up. The dependent variable is either being 
pensioned or not pensioned at follow-up. 
Variable B S.E. Wald P OR 95% CI for B 
Age 0.144 0.045 10.227 0.0014 1.155 1.057; 1.262 
HS 0.150 0.079 3.616 0.0572 1.162 0.995; 1.356 
SOFAS -0.069 0.031 4.855 0.0245 0.933 0.877; 0.992 
Time in MDE 0.152 0.048 9.948 0.0016 1.164 1.059; 1.279 
No vocational
education 1.449 0.644 5.056 0.0245 4.258 1.204; 15.051 
HS = Beck Hopelessness Scale, SOFAS = Social and Occupational Functioning Assessment 
Scale, MDE = Major depressive episode 
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Table 13 Logistic regression model of significant clinical baseline variables, time in 
MDE during the 18-month follow-up, and being on sick leave at baseline. The dependent 
variable is either being pensioned or not pensioned at follow-up.  
Variable B S.E. Wald P OR 95% CI for B 
Gender -1.772 0.813 4.758 0.0292 0.170 0.035; 0.835 
Age 0.141 0.047 9.137 0.0025 1.151 1.051; 1.261 
Time in MDE 0.184 0.049 14.079 0.0002 1.202 1.092; 1.323 
No vocational
education 1.242 0.648 3.670 0.0554 3.461 0.972; 12.327 
Being on sick-leave 
at baseline 1.804 0.688 6.867 0.0088 6.074 1.576; 23.412 
MDE = Major depressive episode.
7.4.2 Treatment 
Pensioned patients had been treated somewhat more intensively than the others. All 
pensioned patients were on antidepressants at baseline, whereas of 165 non-pensioned 
patients, 23 (14%) had none (Fisher’s exact test, p=0.081). At 6 months, of 21 
pensioned patients, 17 (81%) had used antidepressants uninterruptedly from baseline vs. 
87 (53%) of 165 their counterparts (df=1, Chi2=4.930, P=0.026); at 18 months the 
corresponding figures were 14 (67%) of 21 and 70 (42%) of 165 (df=1, Chi2=3.496,
p=0.062). The median number of visits to doctors during the 18 months was also higher 
(6.0) among the pensioned patients than among those not pensioned (2.0) (Mann-
Whitney test, Z=-4.051, p<0.001). The median number of visits to any personnel was 
19.0 vs. 14.0 visits, respectively (NS). 
No other significant differences were found in other aspects of treatment, attitudes 
towards treatment, or adherence to it. All but one (95.2%) of the pensioned and of 142, 
116 (81.7%) of the non-pensioned patients received adequate antidepressant treatment 
in the acute phase of MDE. Antidepressant combinations were received during follow-
up by 5 of 21 (23.8%) vs. 25 of 165 (15.2%). Of 21 pensioned patients, 2 (10%) vs. 26 
(16%) of 165 non-pensioners received weekly psychotherapy. Patients’ attitudes 
towards medication did not differ significantly either; of 21, 1 (5%) pensioned patient 
vs. 27 (16%) of 165 of others reported a negative attitude towards antidepressants. Of 
the pensioned subjects, 19 (95.0%) of 20 reported having taken antidepressants 
regularly or somewhat irregularly, among the non-pensioned of 106, 96 (90.6%). Of the 
pensioned patients of 21, 5 (23.8%) had been hospitalized (1 to 4 times) either during 
baseline or follow-up vs. 33 (20%) of 165 (1 to 14 visits) of those not pensioned. The 
mean length of hospital stay for pensioned patients was 33.8 days (SD 14.9) vs. 44.9 
days (SD 57.3), respectively. 
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8. DISCUSSION 
8.1 Main findings 
The most important finding in the record-based study (I) was that the majority of 
psychiatric patients treated in psychiatric settings were likely to receive antidepressants 
in doses found effective in clinical trials. However, the quality-of-care problems were 
quite different from their past quality-of-care problems. 
Of the baseline factors, the follow-up (Study II) found severity of depression to be the 
dominant factor explaining all types of disability among patients with major depressive 
disorder, as in other studies (Judd et. al., 2000; Sorvaniemi et al. 2003). The preceding 
history of depressive illness, presence of comorbid mental and physical disorders, 
gender, and age were each significantly associated with at least some aspects of 
disability. During follow-up (Study III), concurrently with recovery from depression, 
patients’ overall functioning and social adjustment were markedly alleviated. Although 
multiple factors predicted disability at various time-points, current level of depression 
and cumulative history of depression were the two most robust predictors of disability 
and adjustment. In addition, psychiatric comorbidity, plus social support as perceived 
by the patient were also consistent predictors. Factors associated with being on sick-
leave at baseline were not necessarily identical to those associated with functional and 
social disability or poor adjustment. 
Factors associated with work disability (Study IV) were somewhat different from those 
of disability and adjustment. Many sociodemographic and clinical factors clearly 
predicted long-term work disability among psychiatric patients with MDD. Even after 
adjusting for clinical variables, the sociodemographic factors of older age and lack of 
vocational education independently predicted disability pension. Of the baseline clinical 
predictors, hopelessness was the strongest, but level of disability and lack of vocational 
education also had an effect. Thus those who are most hopeless about their future 
appear to more often eventually be granted a work disability pension. During follow-up, 
slow recovery from depression (time spent in MDEs) was one of the strongest factors 
affecting patients’ work ability. A major public health policy issue is the role of sick-
leaves. Being on sick leave at baseline strongly predicted (OR 6.1) disability pension, 
even after adjusting for all other significant predictors. 
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8.2 Methods 
8.2.1 Study cohorts 
8.2.1.1 Record-based study cohort 
The major strength of this record-based study is that it was based on a large patient 
population representing psychiatric secondary care in Finland’s fourth largest city. We 
could not include patients who had visited private psychiatrists outside the PMCD, or 
the very few treated at Helsinki University Central Hospital. Based on another study 
(Knudsen et al., 1992) and an unpublished epidemiologic survey of the city of Vantaa, 
we estimated our sample to represent two-thirds of all depressed subjects in the general 
population of Vantaa seeking psychiatric treatment (Isometsä & Lönnqvist, unpublished 
data, 1999). Thus, we expect our findings to be generalizable in secondary care settings 
in Finland (Sorvaniemi et al., 1998) in the latter half of the 1990s and, given their 
similarities to findings from some other recent studies, (Bingefors et al., 1997; 
Nurnberg et al., 1999; Sirey et al., 1999; Donoghue, 2000) to psychiatric settings in 
other Western countries as well. 
The data were collected from a computerised database comprising the full psychiatric 
patient records of the catchment area. We consider the quality of these comprehensive 
records available to us to be good, which allowed us to investigate the clinical 
characteristics and the treatments received in more detail than in previous 
investigations.
8.2.1.2 Prospective study cohort 
As in the record-based study, this relatively large cohort also represents well the 
secondary-level psychiatric in- and outpatients from a well-defined urban catchment 
area. Drop-outs from the main cohort during the follow-up were quite rare, because 
87% of the baseline cohort could be interviewed at least once after baseline. In Study 
III, patients who had completed the entire follow-up study represented 72% (193 of 
269) of all the subjects interviewed at baseline, and in Study IV 69% (186 of 269) of the 
baseline cohort. The gender distribution of VDS (73% females) is quite similar to many 
other well-defined MDD cohorts (Stuart et al., 1992, Pepper et al., 1995, Sato et al., 
1996). However, the proportion of women was somehow higher in this age group than 
in some Finnish epidemiological studies (Lehtinen & Joukamaa, 1994 Lindeman et al., 
2000). The over-representation of women might be a result of the different health 
behaviour of men. It is possible that they do not seek help as often as women, and 
perhaps they solve their problems easily with alcohol. 
Lopullinen.pdf   64 14.9.2006   10:36:28
65
8.2.2 Validity and reliability of the diagnoses  
8.2.2.1 Record-based study 
This study was based on clinical diagnoses of depression, the validity of which was 
randomly estimated as good according to data from psychiatric records. The possibility 
of false-negative, undiagnosed cases cannot, however, be excluded. Psychiatric records 
were carefully investigated to exclude false-positive cases likely to have had some other 
psychiatric disorder. 
8.2.2.2 The VDS cohort study 
In the follow-up study, unlike in any preceding study, the effect of the whole spectrum 
of Axis I and II comorbidity of MDD patients on their social and occupational 
functioning, social adjustment, and work ability were possible to examine. Axis I 
diagnoses were made by SCAN-interview having an excellent reliability (kappa=0.86) 
for the diagnosis of MDD. Axis II diagnoses were made by the semi-structured SCID-II 
interview for DSM-III-R, because the SCID II for DSM-IV was not yet available in 
February 1997. Differences between DSM-III-R and DSM-IV were taken into account. 
8.2.3 The life-chart methodology 
During the follow-up we assessed the course of depression by using a life-chart 
methodology. This Longitudinal Interval Follow-up Evaluation (LIFE) was first used to 
investigate the outcome of depression in the NIMH-CDS (Keller et al., 1987). We 
inquired about change points in the psychopathologic state, using probes related to 
important events. In the VDS the outcome of MDD was investigated by use of a graphic 
life chart, which is quite similar to the LIFE. 
8.2.4 Measuring functioning, adjustment, and work disability 
The SOFAS scale was used to measure global level of functioning at the time of 
evaluation. This scale measures purely the level of social and occupational functioning, 
without taking symptoms into account.  
8.2.5 Limitations of the studies 
8.2.5.1 The record-based study (I) 
The validity of depression diagnoses in this study were estimated to be good, but 
making diagnoses only according to psychiatric records involves many difficulties. The 
possibility of false-negative, undiagnosed cases also cannot be excluded. Since the 
study population was based on the 12-month prevalence of depression in the PMCD, 
inclusion of cases was influenced both by the incidence of depression and by the 
duration of treatment period, which enriches chronic patients in the population. 
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However, as such, the population accurately represents the caseload of the attending 
personnel. Work disability and pensions in this study were based on the data in the 
medical records. 
8.2.5.2 Baseline findings of the VDS cohort study (II) 
Measuring pure disability without taking into account severity of symptoms is the ideal, 
but some contamination of the symptom ratings is hard to avoid, even with the SOFAS 
with a good validity (Hilsenroth et al., 2000; Hay et al., 2003). Furthermore, patients’ 
insight regarding their disability in interview, or in the self-reported SAS-SR, may vary. 
Moreover, as most of the SAS-SR subscales are relevant only for a subgroup of 
patients, the overall score comprises a variable composition of subscales relevant for 
each of the patients, but uniformly scored. Whereas the psychometric properties of the 
subscales were acceptable in all cases, and in some of them were good, some others 
were far from ideal. We therefore considered it important to study not only patients’ 
views of their functional status, but also their objective functioning and ability to work. 
8.2.5.3 Functional disability and social adjustment (III) 
We analysed only those 193 who remained unipolar and had complete data from every 
interview. Those not included were significantly younger than the study cohort, but in 
other characteristics the groups did not differ. We used three main measures of 
disability, objective SOFAS and subjective self-rated SAS-SR and number of days 
spent ill in bed. Measurement of pure functional disability comprises numerous 
methodological difficulties. SOFAS and SAS-SR include some problems mentioned 
earlier. Accuracy of estimating number of days in bed may vary. In order to exclude 
possible circularity, we tested the correlations between SAS-SR and PSSS-R with and 
without family-related items, and both of them gave the same results. Similarly, current 
depressed state complicates diagnosing current comorbid mental disorders, particularly 
personality disorders, or assessments of personality features. However, this is not 
different from clinical diagnostic evaluations, which must be based on the information 
currently available. We decided not to use treatment received as a predictor for 
functional outcome, as it was largely driven by perceived need (i.e., severity of 
depression), and we assumed its impact on functional status to be mediated via impact 
on outcome of depression per se, which was an important predictor. Finally, as the 
characteristics of our patients and outcome of their depression and functional status are 
largely in line with other studies (Isometsä et al. 2000; Judd et al. 2000a; Hays et al. 
2001; McDermut et al. 2001), we believe that our findings are mostly generalizable to 
other psychiatric settings. 
8.2.5.4 Long-term work disability study (IV) 
Our study sample comprised only 69% (186 of 269) of the unipolar MDD patients of 
our initial cohort since only those patients who were potential labour force contributors 
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at baseline were included. Moreover, part of the initial cohort dropped out, and some 
switched to bipolar disorder. The relatively small number of pensioned patients limits 
the statistical power of results and might also increase the risk for spurious findings. 
However, our findings were found to be statistically highly significant. The main 
measure of disability was SOFAS, which may have some contamination between 
symptoms of depression and those of comorbid disorders. As this measure contains 
ability to work as one of its major domains, it was clearly circular with being on sick 
leave, and could not be used as a predictor in all analyses. 
8.3 Treatment received for depression in psychiatric care (Study I) 
The main finding in this study was that the large majority of depressed patients received 
adequate antidepressant treatment, although often in low doses. Inadequate treatment 
was common only among those receiving TCAs, whereas treatment with newer 
antidepressants almost always occurred with doses found to be effective in clinical 
trials. In the earlier studies conducted in the 1980s, antidepressant treatment received by 
psychiatric patients was generally found to be absent or inadequate (Keller, 1988). 
Some recent smaller studies (Sorvaniemi et al., 1998) have indicated improvement in 
the quality of care during the last decade. It should be noted that mirtazapine and 
venlafaxine entered the Finnish market in 1996, so only a few patients in our study 
received them. The median duration of the treatment period was found to be over one 
year; thus, acute, continuation, and maintenance treatment phases were probably 
included in most cases. The modest intensity of the treatment provided, largely due to 
limited resources in terms of monitoring antidepressant treatment as well as 
psychosocial treatments, is clearly a problem. Most patients visited psychiatrists only 
one to three times. However, even considering this, we found the psychiatrists to have 
been quite conservative in switching antidepressants. This was true even when poor 
response was obvious, e.g., in those granted a disability pension. 
Depression-related functional disability (Broadhead et al., 1990; Wells et al., 1989) and 
the necessity of disability pensions (Isometsä et al., 2000) due to depression are major 
losses to both the individual and society. Treatment of depression has been shown to 
markedly reduce depression-related disability (Mintz et al., 1992). In our sample, one-
fifth of those not already receiving a disability pension were granted one during the 
treatment period investigated. Patients in this subgroup were considerably older and 
more severely ill, used more concomitant psychotropic medication, and had slightly 
more visits to professionals than did patients in other subgroups. Nevertheless, about 
two-thirds of these patients (67%) received a disability pension after only a single trial 
of an antidepressant. 
We have also made a similar finding in another nationally representative study of 
patients with major depression who were granted a disability pension in Finland 
(Isometsä et al., 2000). Furthermore, use of TCAs, often in inadequately low doses, was 
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more common (31% vs. 11%) among patients granted a disability pension during the 
study period than among the other patients. While it remains unknown whether more 
intensive pharmacotherapy or psychosocial treatment could have prevented their 
permanent disability, it is at least obvious that more intensive treatment efforts are 
warranted. Our concern is that cutting costs in the quality of care may result in much 
higher permanent costs to society. 
8.4 Functional and work disability in depression (Study II) 
Severity of depression was the dominant factor explaining all types of disability among 
patients with major depressive disorder, but not the sole factor. The preceding history of 
depressive illness, presence of comorbid mental and physical disorders, gender, and age 
were each significantly associated with at least some aspects of disability. Furthermore, 
factors associated with functional and social disability or poor adjustment were not 
necessarily identical to those associated with being on sick-leave. 
In the VDS cohort study we used the SOFAS scale to measure global level of 
functioning at the time of evaluation. Our patients suffered from variable functional 
impairment, although moderate to serious on average. The level of disability emerged 
as strongly associated with the severity of depression, which accords with most studies 
of clinical depression (Wells et al., 1989; Tollefson et al., 1993; Leader & Klein, 1996; 
von Korff et al., 1992) including the NIMH Collaborative Depression Study (Judd et al., 
2000a), exceptions being some studies with relatively homogeneous inpatient 
populations (Goethe & Fischer, 1995; Lyness et al., 1993). 
However, even after adjusting for current severity and other possible confounding 
factors, the number of previous episodes of depression was significantly associated with 
current level of functioning. Our results further support findings that poorer functional 
status is associated with older age (Lyness et al., 1993) and personality disorders 
(McDermut et al., 2001; Skodol et al., 2002). There were also interesting, albeit slight 
differences between our findings with the SOFAS and the SAS-SR. Global functional 
status estimates with the SOFAS appear most strongly influenced by severity and 
recurrences of depression. In contrast, the SAS-SR is an indicator of broader social 
adjustment, and more reflects problems related to other aspects of psychopathology, 
such as substance abuse, personality disorders, and phobic avoidance. Nevertheless, 
severity of depression was still the major factor explaining problems in social 
adjustment as measured by the SAS-SR overall scale. Differences between age groups 
or genders were seen only in the family unit subscale, which reflects functioning in 
family roles. 
Depression leads to major costs to society due to decreased work performance and days 
lost from work (Mintz et al., 1992; Kessler & Frank, 1997; Hensing et al., 2000, Druss 
et al., 2000 Druss et al., 2001). In our representative sample, two-fifths of the employed 
patients with MDD were on sick-leave. This was more common among females, older 
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patients, and those with somatic diseases, as in earlier reports (Hensing et al., 2000; 
Lyness et al., 1993). It appears that many patients, particularly males, with moderate to 
severe depression are working despite obvious impairments. Of particular clinical 
importance is the finding that not only current severity, but also number of previous 
episodes were clearly related to being on sick-leave. Other studies have found recurrent 
depression to be a significant predictor of poor functioning (Basso & Bornstein, 1999; 
Sheline et al., 1999) or poor work adjustment (Bauwens et al., 1998), but this is the first 
to show its relation to actual work absence, even adjusting for current severity of 
depression. This finding emphasizes the important role of maintenance treatment to 
prevent recurrences and work disability related to MDD Alternative explanations, such 
as patients’ learning to seek sick-leaves after successive episodes, or greater acceptance 
of sick-leave by doctors in cases with previous episodes, are possible but unlikely, 
given the consistently lower SOFAS in recurrent cases. Therefore, whether actual work 
disability (in contrast to sick-leave) really increases after each successive episode of 
depression should be investigated in prospective studies. 
8.5 Functional disability and social adjustment in MDD (Study III) 
Concurrently with recovery from depression, patients’ overall functioning and social 
adjustment were markedly alleviated. Although multiple factors predicted disability at 
various time-points, current level of depression and cumulative history of depression 
were the two most robust predictors of disability and adjustment. In addition, 
psychiatric comorbidity, plus social support as perceived by the patient were also 
consistent predictors. 
In this study was hypothesised that not only would current severity of depression affect 
functioning, but also that the preceding course of illness would have an independent 
effect on level of functioning. Findings from earlier studies have not been fully 
consistent. For example, in a meta-analysis, Mintz et al. (1992) found alleviation of 
depression and improvements in functional capacity to work to follow a somewhat 
different trajectory. In contrast, Judd et al (2000a) in the NIMH Collaborative 
Depression Study found functional disability to be largely state-dependent, patients 
were disabled while depressed, but when asymptomatic, level of functioning improved 
markedly. In our study, both current severity and preceding course of depression were 
powerful predictors of functional status, as hypothesised. It may well be true that 
depressive episodes have enduring adverse consequences for life structure (Coryell et 
al. 1993). Alternatively, it is possible that their effect is a reflection of more 
fundamental illness processes such as long-term deficiencies in neuropsychological 
functioning caused by repeated illness episodes (Basso and Bornstein, 1999). Previous 
follow-up studies have found that severity (Melartin et al. 2004) and recurrence of 
depression (Ormel et al. 2004) are the most important independent predictors of 
symptomatic outcome. The present findings highlight the importance of the cumulative 
course of the illness specifically for disability in depression. 
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Another hypothesis was that the presence of psychiatric comorbidity (Isometsä et al. 
2000; McDermut et al. 2001), perceived social support (Hays et al. 2001), and certain 
personality traits (Lyness et al. 1998) would each determine disability independently. 
Overall, this prediction appears to have been mostly correct. We examined all comorbid 
Axis I and II disorders and found comorbid anxiety symptoms to be a determinant of 
functional disability and social adjustment over the whole follow-up period. Anxiety 
disorders are often temporally primary and long-lasting, and may both predispose to and 
worsen outcome of depression (Wittchen et al., 2000; Melartin et al., 2004). In contrast, 
it appeared that comorbid personality disorders per se had only a limited independent 
effect on disability. However, similar to findings concerning elderly depressed patients 
(Lyness et al. 1998), we found neuroticism as a personality trait affecting social 
adjustment. Even after adjusting for possible confounders and level of depression, 
patient-perceived social support seemed to play an important role in our cohort, more in 
ours than in other studies (Hays et al. 2001). Overall, it seems that disability among 
patients with depression cannot be explained merely in terms of current or preceding 
depression, but is also significantly related to symptoms of comorbid disorders, 
personality traits, and the social network as the patient perceives it. 
8.6 Long-term work disability in MDD (Study IV) 
Many sociodemographic and clinical factors clearly predict long-term work disability 
among psychiatric patients with MDD. Even after adjusting for clinical variables, the 
sociodemographic factors of older age and lack of vocational education independently 
predicted disability pension. Of the baseline clinical predictors, hopelessness was the 
strongest, but level of disability and lack of vocational education also had an effect. 
Thus those who are most hopeless about their future appear to more often eventually be 
granted a work disability pension. During follow-up, slow recovery from depression 
(time spent in MDEs) was one of the strongest factors affecting patients’ work ability. 
A major public health policy issue is the role of sick leaves. Being on sick-leave at 
baseline strongly predicted (OR 6.1) disability pension, even after adjusting for all other 
significant predictors. 
Older age was a major factor predicting work disability and disability pension, even 
after adjusting for other predictors. After adjusting for other possibly significant factors, 
lack of vocational education clearly predicted long-term work disability. This finding 
was convergent with a US study by Elinson et al. (2004), although we found no 
differences related to marital status. Being granted a disability pension for depression is 
obviously dependent on other factors in addition to clinical ones. 
Several clinical factors were found to significantly predict long-term work disability. Of 
the baseline variables, hopelessness was more pronounced and functional disability 
worse among the pensioned than among the other patients. In our view, subjects who 
see their future in negative terms may be more inclined to cope with their depression by 
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seeking a long-term disability pension. Furthermore, poor level of functioning in the 
acute phase is, hardly unexpectedly, a strong predictor of disability also during follow-
up. Contrary to the findings of Spijker et al. (2004) in the Dutch general population, 
duration of MDE was in pensioned patients significantly longer, and one-third did not 
reach even partial remission. At six months, the differences between groups were 
greatest in nearly all measures, which also reflects the slow recovery from depression. 
Severity and number of previous episodes of depression and comorbidity were not 
effective predictors of long-term work disability; their role was overshadowed by the 
impact of time spent in MDEs during follow-up. 
Surprising was the strong role of being on sick leave at baseline as a predictor of 
disability pension later, even after adjusting for the other predictors for disability 
pension. Thus, of patients with apparently similar clinical characteristics, those who are 
currently on sick leave seem to have a markedly higher probability of pension in the 
future. This finding is unlikely to be tautological, i.e., merely due to preceding long 
sick-leaves being a precondition for a pension to be granted. The study design was 
prospective, and the majority of patients on sick-leave at baseline returned to work or 
unemployment during follow-up. However, a major limitation in our study was that we 
were not able to measure motivational factors related to work that may also influence 
seeking a pension. To our knowledge, this research area has not been investigated in 
other studies concerning depression and disability, but it is obviously a major health 
policy issue. Studies of somatic diseases (Rabkin et al., 2004) have found that returning 
to work is difficult after time out of work-life. The extent to which sick leaves have 
adverse, disability-reinforcing or negative motivational consequences among patients 
with depression warrants further investigation. 
A previous study focusing on the early 1990s (Isometsä et al, 2000) found 
pharmacotherapy among subjects granted a disability pension for depression to have 
been largely suboptimal. In the present study, all of the pensioned patients received 
antidepressants at baseline, and in nearly all cases, the treatment was classified as 
adequate. Thus, disability is unlikely to have been caused by inferior treatment. 
However, given the high costs related to disability, the intensity of treatment provided 
was far from optimal. 
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9. CONCLUSIONS AND FUTURE IMPLICATIONS 
9.1 Conclusions 
Major depressive disorder is a common illness causing severe human suffering and 
short- and long-term disability, and thus leading to enormous economic costs to both 
the individual and society. Although this record-based study found an emerging 
perception of improved quality of pharmacotherapy in psychiatric settings — with the 
exception of treatment with tricyclics — problems in the quality of care for depression 
in psychiatric settings are more likely to be related to suboptimal intensity and 
monitoring of treatment than to mere lack of treatment. Too few visits to psychiatrists 
and other professionals to allow systematic follow-up and psychosocial treatments, 
exclusive reliance on the low end of the dose range of antidepressants, limited number 
of antidepressant trials or augmentations, and acceptance of permanent disability 
without first pursuing vigorous treatment are all likely to be major problems in current 
psychiatric settings. However, it must be noted that this study represents the treatment 
situation nearly ten years ago. Therefore currently the treatment situation may be 
different.
The prospective part of this thesis investigated factors predicting problems in social 
adjustment, and functional and work disability. To better find and understand those we 
studied comprehensively MDE patients’ Axis I, II, and III comorbidity and a large 
variety of sociodemographic and clinical factors.  
During the current depression period, the most important single factor explaining 
disability appears to be severity of depression. Lack of perceived social support was one 
of the most important factors associated with disability. However, factors such as 
recurrent depression, older age, anxiety disorders, particularly phobic disorders, 
alcoholism, or personality disorders also probably contribute. Somatic diseases may be 
important among older patients. Furthermore, the importance of any of these factors as 
predictors of disability appears to vary somewhat depending on the area of life 
investigated. Finally, factors associated with functional, social or work disability, or 
absence from work, are unlikely to be identical. 
During the course of treatment and recovery from depression, the factors predicting a 
patient’s disability are somehow different from those in the beginning of the episode. 
This prospective study indicates that the current level of functioning and social 
adjustment of a patient with depression is predicted not only by current state, but also 
by the preceding history of depression. Furthermore, the presence of comorbid 
psychiatric disorders, personality trait neuroticism, and perceived social support also 
significantly influence level of functioning and social adjustment. Predictors of long-
lasting work disability are multiple sociodemographic and clinical factors, not only 
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clinical factors. Baseline level of functioning and duration of depressive episodes are 
key clinical predictors of future disability. 
9.2 Clinical implications 
Recognition of depression and specifically the risk factors associated with functional 
and work disability such as older age, lack of perceived social support, comorbidity, 
earlier history of depression, and current functioning are key factors in avoiding the 
necessity to pension individuals. Being on sick-leave has its specific effect on the later 
outcome of depression and restoration of functional and work ability. 
Early beginning of treatment and sufficiency of treatment resources are necessary 
despite the current lack of psychiatrists. Reducing time spent depressed in the acute 
phase by optimal treatment is one of the most important aims for reducing long-term 
disability. Otherwise lengthened sick-leaves or even work disability pensions are 
possible results. 
Management of depression-related disability is challenging. Pharmacological treatment 
seems to be minimally adequate (patients often receive too small antidepressant doses 
though formally adequate ones). Treatment of refractory depression is the most 
challenging indicating integrated treatment approaches. However, problems in the 
intensity and monitoring of treatment stand in the way of patients’ rapid recovery and 
thus restoration of their functional and work ability. 
9.3 Future implications for research 
Factors associated with functional and specifically long-term work disability have been 
researched surprisingly seldom. When one takes into account especially the huge costs 
connected with depression treatment and the disability it causes, this is worrisome. 
Research is needed on treatment to better identify those special treatment methods 
helping high risk patients to recover sooner and maintain their functional abilities. 
The independent and significant role of sick-leaves predicting pensioning was 
unexpected. The positive and negative consequences of sick-leave also require 
elucidation.
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